Blood - McMaster Experts

publication venue for

Aberrant Splicing of MBD1 Reshapes the Epigenome to Drive Convergent Myeloerythroid Defects in MDS 2023
Disparities in the Enrollment of Racialized, Ethnic Minority, and Older Adults in Randomized Trials of Acute Myeloid Leukemia: A Systematic Review 2023
Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting 2023
Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry 2023
Identifying Stress Granules As Determinants of Leukemia Stem Cell Maintenance and Stress Adaptation 2023
Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis 2023
Restrictive Versus Liberal Red Blood Cell Transfusion Strategies for Patients with Hematologic Malignancies Receiving Intensive Chemotherapy 2023
Updated Protocol for the Phase 3, Randomized, Double-Blinded Lex-210 Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Factor Xa Inhibitor Therapy 2023
Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial 2023
A Novel Substrate for Assessing Thrombin Activity in Whole Blood 2022
Activating a Non-Genetic MYC-Regulating Pathway Sensitizes Acute Myeloid Leukemia to Bromodomain Inhibition 2022
Anything but Cookbook Medicine: Exploring the Influence of Supervisor Practice Variability on Resident Learning in Thrombosis Medicine 2022
Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma 2022
Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP 2022
Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada 2022
Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute 2022
Hemostatic Profile at Diagnosis in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of Cases from the Literature 2022
Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database 2022
Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma 2022
Impact of Thrombotic Events Occurring during Active Treatment of Leukemia on the Overall Survival and Event-Free Survival: A Systematic Review 2022
International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation 2022
Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat 2022
Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study 2022
Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study 2022
Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status 2022
Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial) 2022
Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis 2022
Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy 2022
Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database 2022
Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry 2022
Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry 2022
Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database 2022
The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab 2022
Universal Premedication for Pegylated (PEG)-Asparaginase Treatment in Children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LLy) Has No Impact on Frequency of Hypersensitivity Reactions 2022
Use of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Agents for Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis 2022
Values and Preferences Towards Antithrombotic Therapy in Patients with Myeloproliferative Neoplasms: A Qualitative Study 2022
Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL) 2022
Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers 2022
Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study 2021
A Novel Methodology for Building Longitudinal, PatientCentric Real World Datasets in Hemophilia A 2021
Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) 2021
A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History 2021
Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial 2021
Diagnostic Accuracy of D-Dimer for Pulmonary Embolism and Lower Limb Deep Vein Thrombosis Testing in People with Cancer: A Meta-Analysis 2021
Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study 2021
Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis 2021
Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry 2021
Fitness Assessment of Elderly Patients with AML and Outcomes 2021
Guiding the Standardization in Acute Leukemia Service Delivery through the Development of Organizational Requirements 2021
Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium 2021
Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma 2021
Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database 2021
Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study 2021
Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience 2021
PLAGL2 Independently Drives Aberrant Erythropoiesis and Initiation of Preleukemic State 2021
Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma 2021
Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study 2021
Physician and Patient Beliefs and Preferences in Pulmonary Embolism and Deep Vein Thrombosis Testing in People with Cancer 2021
Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry 2021
Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis 2021
Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers 2021
Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry 2020
Decision making factors that influence treatment options for an autologous stem cell transplant for older adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods. 2020
Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability 2020
Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database 2020
Emergency Department Quality of Care for Sickle Cell Disease in Ontario, Canada: A Population-Based Matched Cohort Study 2020
Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset 2020
Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium 2020
Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up 2020
Impact of Thromboembolism on Overall and Event-Free Survival in Children with Acute Lymphoblastic 2020
Is tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) Database. 2020
Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database 2020
Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry 2020
Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A 2020
Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. 2020
Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study 2020
Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes 2020
Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments 2020
Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study 2020
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma 2019
A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus 2019
Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review 2019
Anti-FVIII Antibody and Inhibitor Development Patterns in Hemophilia A Mouse Models: A Systematic Review 2019
Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study 2019
Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure 2019
Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency 2019
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency 2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel 2019
Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A 2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products 2019
Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors 2019
Epidemiology, Diagnosis and Management of Neonatal Thrombosis 2019
Evaluating the Quality of Systematic Reviews & Meta-Analyses Published on Direct Oral Anticoagulants in the Past 5 Years 2019
Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral 2019
Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study 2019
Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort 2019
Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment 2019
Identifying Patterns of Inappropriate Plasma Transfusion Practices Using a Novel Multicenter Electronic Data Audit: Over 80 Percent of Plasma Transfused Is Inappropriate 2019
Impact of Iron Supplementation on Patient Outcomes in Women Undergoing Gynecological Procedures: Systematic Review and Meta-Analysis of Randomized Trials 2019
Impact of KIR/HLA Incompatibilities after Posttransplant Cyclophosphamide Based T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation 2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) 2019
Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study 2019
Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death 2019
Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial 2019
Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4 2019
Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial 2019
Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh) 2019
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study 2019
Predictors of Disease Progression and Survival in Patients with Myelodysplastic Syndrome Secondary to Inherited Bone Marrow Failure Syndromes 2019
Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests 2019
Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience 2019
Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial 2019
The Impact of Identifying the Syndromic and Genetic Diagnoses on Hematopoietic Stem Cell Transplantation Outcome in Patients with Inherited Bone Marrow Failure Syndromes 2019
The Splicing Factor RBM17 Supports Leukemia Stem Cell Self-Renewal 2019
Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort 2019
Venous Thromboembolism in Lower Extremity Amputees: A Systematic Review of the Literature 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis 2019
Blood Loss Due to Laboratory Testing in Critical Care Patients: A Retrospective Cohort Study 2018
Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform 2018
Enhanced Zebrafish Xenograft Platform Improves Hematopoietic Stem Cell Engraftment and Leukemogenesis 2018
Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review 2018
Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency 2018
High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada 2018
How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations 2018
Impact of Donor Chimerism-Guided Immunomodulation after Allogeneic Stem Cell Transplant on the Outcome of Patients with AML and MDS 2018
Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013 2018
Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis 2018
LSD1 Inhibitors Induce Fetal Hemoglobin in Primary Human Erythroid Cells 2018
Mediastinal Mass, Triglycerides Level Above 1000mg/Dl and Intensive Dexamethasone and Asparaginase Treatment Are Risk Factors for Cerebral Sinus Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon 2018
Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis 2018
Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism 2018
Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada 2018
Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant 2018
Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study 2018
Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study 2018
Regulating Transcriptional Co-Activator PGC-1α for the Treatment of Sickle Cell Disease 2018
Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI) 2018
Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia 2018
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial 2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel 2018
T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma 2018
The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines 2018
The Predictive Value of Intracellular Imatinib Levels in Chronic Myeloid Leukemia 2018
Thrombin Generation Impairments in Platelet Function Disorders 2018
Urgent Management of Bleeding in Immune Thrombocytopenia: Towards a Standardized Protocol in the Emergency Department 2018
Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia 2018
Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World 2017
Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011 2017
A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study 2017
Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001 2017
An Enhanced Zebrafish Xenograft Model to Study the Behavior of Human Hematopoietic Stem Cells and Patient Derived Leukemia In Vivo 2017
Anti-CD20 Monoclonal Antibody Therapy for Immune Modulation Across a Range of Autoimmune Diseases 2017
Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial 2017
Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study 2017
Characteristics of Venous Thromboembolism in Patients with Acute Leukemia 2017
Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) 2017
Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A 2017
Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial 2017
Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001 2017
Distribution of Lymphomas in Mexico: A Descriptive Study 2017
Emergency Management of Patients with Immune Thrombocytopenia and Severe Bleeding 2017
Enforcing Post-Transcriptional Circuitries to Achieve Human Hematopoietic Stem Cell Expansion 2017
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial 2017
Evaluation of Plasma-Derived FVII Efficacy for the Treatment of Bleeding in a Murine Model of Hemophilia a 2017
Genotype-Phenotype Correlation and Molecular Heterogeneity in Pyruvate Kinase Deficiency: Data from the PKD Natural History Study 2017
Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease: Analyzing the Association of Insurance and Socioeconomic Status Among Children Undergoing Hematopoietic Cell Transplantation 2017
LSD1 Inhibition Leads to Differentiation in Hoxa9/Meis1-but Not in MN1-Induced Acute Myeloid Leukemia 2017
Long Term Followup of Sickle Cell Disease Post Hematopoietic Stem Cell Transplant from Uganda 2017
Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results 2017
Multimerin-1 Binds to Specific Motifs in Vessel Wall Collagens and Contributes to Thrombosis: Novel Insights Regarding the Mechanisms That Support Human and Mouse Platelet Adhesion 2017
Optimal Timing of Starting Thromboprophylaxis for Patients with Acute Spinal Cord Injury: A Cross-Sectional Survey of Canadian Spine Surgeons 2017
Oral Anticoagulant Dosing, Administration, and Storage: A Cross-Sectional Survey of Canadian Health Care Providers 2017
Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) 2017
Performance Characteristics of a Novel Platelet Viability Assay for Heparin-Induced Thrombocytopenia 2017
Pharmacokinetics and Pharmacodynamics of Ionis-FXI_Rx, an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis 2017
Population Pharmacokinetics Profiling to Tailor Prophylaxis in Hemophilia a Patients: A Pilot Feasibility Study 2017
Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial 2017
Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2017
Re-Analysis of Next Generation Sequencing Gene Panel Data By Normalized Coverage Values Reveals Previously Undetected Copy Number Variations in Inherited Bone Marrow Failure Syndromes 2017
Serum Ferritin Underestimates Liver Iron Concentration in Patients with Homozygous Alpha-0 Thalassemia 2017
Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study 2017
The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation 2017
The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism 2017
The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery 2017
The Identification of the Amino Acids on Platelet Factor 4 That Bind Pathogenic Antibodies in Heparin-Induced Thrombocytopenia 2017
The Real-World Treatment of Polycythemia Vera: Adherence to Treatment Guidelines and Outcomes 2017
Using Automatic Cell Counts to Calculate the I:T Ratio for Investigation of Early Onset Neonatal Sepsis 2017
Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma 2017
An individual participant data meta-analysis of 13 randomized trials to evaluate the impact of prophylactic use of heparin in oncological patients 2017
A Pilot Study in Cancer Patients with Central Venous Catheter Associated Deep Vein Thrombosis in Upper Extremity Treated with Rivaroxaban (Catheter 2) 2016
Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries 2016
Anticoagulation Therapy for Thrombotic Events in Paediatric Cancer Patients with Low Platelet Counts 2016
Attitudes Toward Prenatal Diagnosis and Pregnancy Management in Carriers of Hemophilia: A Qualitative Analysis Exploring the Views of Carriers in Southern Alberta 2016
Bleeding Risks Associated with Confirmed Platelet Dense Granule Deficiency and/or Impaired Aggregation Responses 2016
Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study 2016
Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study 2016
Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review 2016
Development of Platforms to Phenotype Variants of Uncertain Significance in VWF 2016
Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease? 2016
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL 2016
Elucidating the Thrombogenic Risk of Non-O Blood Groups in Children with Acute Lymphoblastic Leukemia (ALL): Is Von Willebrand Factor a Culprit ? 2016
Evaluation of Mortality during Treatement of Acute Myeloid Leukemia in Patients According to Morocco National AML-MA-2011 Protocol in Casablanca 2016
Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001 2016
Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure 2016
Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL) 2016
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia 2016
Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT 2016
Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial 2016
Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells 2016
Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq®, a New Generation Recombinant FVIII of Human Origin 2016
Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives 2016
Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate®) 2016
Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium 2016
LSD1 Inhibition Induces Differentiation and Reduces the Frequency of Leukemia-Initiating Cells in Hoxa9/Meis1-Induced Acute Myeloid Leukemia 2016
Megakaryocyte Apoptosis in the Bone Marrow of Patients with Immune Thrombocytopenia 2016
Outcome of Acute Myeloid Leukemia in Children and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco 2016
Outcome of acute Myeloid Leukemia in Adults Patients Treated According to Morocco National AML-MA-2011 Protocol in Casablanca, Morocco 2016
Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review 2016
Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis 2016
Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP 2016
Pilot Study of Online Learning Modules for Hemoglobinopathy Education in Canadian Hematology Training Programs 2016
Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism 2016
Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements 2016
Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001 2016
Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa 2016
Rwd Study for Epidemiology and Characteristics of Patients with Multiple Myeloma in Italy 2016
Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma 2016
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial 2016
Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl <30 Ml/Min from the Trivet Study 2016
Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis 2016
Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) 2016
The Effect of Platelet Transfusion on Death in the Intensive Care Unit 2016
Thrombocytopenia and Microangiopathic Hemolytic Anemia Precipitated By Acute Pancreatitis: A Single Center Experience of Five Cases 2016
Treatment Outcome of North American Patients with Adult T-Cell Leukemia/Lymphoma: Princess Margaret Cancer Centre Experience 2016
Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial 2016
Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis 2016
A Candidate Trans-Acting Modulator of Fetal Hemoglobin Gene Expression in the Arab-Indian Haplotype of Sickle Cell Anemia 2015
A Humanized Zebrafish Transplant Model Expressing CXCL12 Provides an Enhanced In Vivo Therapeutic Screening Platform for T-ALL 2015
A Library of Sickle Cell Anemia Induced Pluripotent Stem Cells of Diverse Haplotypes and Ethnicities 2015
A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes 2015
Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange 2015
Acute Myeloid Leukaemia in Children: Preliminary Results of a National Protocol in Casablanca, Morocco 2015
An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy 2015
Assessing Disease Stability of Patients with Myelodysplastic Syndrome for an Age of Blood Randomized Controlled Trial: A Chart Review 2015
Biological Rational for the Use of Heparin in Septic Shock: Translational Data from the Halo Pilot RCT 2015
Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis 2015
Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes 2015
Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER (R) and RE-COVER II (TM) 2015
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen 2015
Effect of Asparaginase and Dexamethasone on FVIIa-at Complex and F1.2 in Children with Acute Lymphoblastic Leukemia: Evidence of Hypercoagulable State 2015
Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery 2015
Estrogen Receptor Beta Is a Novel Target in Acute Myeloid Leukemia 2015
Favorable Risk Group Acute Myeloid Leukemia in Children and Young Adult Treated in Uniform Protocol in Casablanca, Morocco. a Preliminary Analysis 2015
Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 2015
Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease 2015
Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study 2015
Low Molecular Weight Heparin for Prevention of Placenta-Mediated Pregnancy Complications: An Individual Patient Data Meta-Analysis 2015
Management of Osteonecrosis By Adult and Pediatric Sickle Cell Providers 2015
Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry 2015
Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review 2015
Novel RUNX1 Mutation in a Family with an Uncharacterized Secretion Defect 2015
Outcomes of Low-Molecular-Weight Heparintreatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors 2015
PLAG1 and USF2 Regulate Primitive Hematopoietic Expression of Musashi-2 2015
Platelet Phosphatidylserine Exposure, Survival and Blood Coagulation in Mice Lacking TMEM16F 2015
Polymorphisms Associated with the Arab-Indian Haplotype of Sickle Cell Anemia Are Candidate Fetal Hemoglobin Gene Modulators 2015
Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis 2015
Red Cell Antigen Genotyping Compared to Standard Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization 2015
Risk Factors Predictive of Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism 2015
Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study 2015
Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study 2015
Safety and Efficacy of Mini-CHOP-R Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in Very Elderly Patients: A Quality Assurance Study 2015
Serum Ferritin Is Not Sensitive or Specific for the Diagnosis of Iron Deficiency in Patients with Normocytic Anemia 2015
Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis 2015
The JAK1/2 Inhibitor Momelotinib Does Not Inhibit Thiamine Uptake in Vitro 2015
The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status 2015
The Quality, Content, Accuracy and Readability of Information about Sickle Cell Anemia on the Internet 2015
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL) 2015
Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis 2015
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors 2014
A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or Refractory TTP 2014
A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191 2014
A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia 2014
Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12 2014
Analysis of (δβ)0 Thalassemia and HPFH Deletions Suggest a Hierarchy of Cis-Acting Elements Regulating Fetal Hemoglobin Gene Expression. 2014
Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up 2014
Application of Novel Next Generation Sequencing Gene Panel Assay to Genetic and Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes 2014
Assessment of HbF QTLs Affecting Disease Severity and Genetic Analysis in Patients Homozygous for Codon 8 (-AA) beta(0)-Thalassemia Mutation 2014
BCL11A enhancer Haplotypes Are Associated with the Distribution of HbF in Arab-Indian and African Haplotype Sickle Cell Anemia but Not the Different Population Levels of HbF 2014
Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study 2014
Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis 2014
Characterization of a Transcript Found within the HBS1L-MYB Intergenic Region 2014
Compound Heterozygosity for Hb S and a Novel Deletion of Dnase I Hypersensitivity Sites HS3 and HS4 of beta-Globin Locus Control Region Results in Hb S/beta(+)-Thalassemia Phenotype 2014
Delta-like Ligands Expressed By Stromal Cells in Secondary Lymphoid Organs Deliver an Early Pulse of Notch Signaling and Drive T Cell Pathogenicity in Acute Graft-Versus-Host Disease 2014
Difficulties in Establishing the Cause of Thrombocytopenia Among Ambulatory Patients Referred to Hematology: An Agreement Study 2014
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis 2014
Hemoglobinopathy Education in Canadian Hematology Training Programs: How Much Are Residents Learning? 2014
High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia 2014
Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II 2014
Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY 2014
Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience 2014
Iron Deficiency As a Common Treatable Cause of Chronic Normocytic Anemia 2014
Low Dose Oral Vitamin K Does Not Increase Time in Therapeutic Range: Results of a Multicentre Clinical Trial 2014
Multisystem, Induced Pluripotent Stem Cell (iPSC) Modeling Reveals a Role for Growth Differentiation Factors (GDFs) in the Etiology of beta Thalassemia and Ineffective Erythropoiesis 2014
Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry 2014
Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial 2014
Post-Hoc Analysis of RE-MEDY (TM) Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism 2014
Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure 2014
Retrospective Evaluation of Patients Referred for Hemochromatosis Genetic Testing 2014
Risk Factors for Poor Survival after Hematopoietic Stem Cell Transplantation in Inherited Bone Marrow Failure Syndromes 2014
Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates 2014
TMEM16F Deficiency Causes a Strain-Dependent Lethality in Mice and Reduced Phosphatidylserine Exposure on Heterozygous As Well As Homozygous Deficient Mouse Platelets 2014
The Mcmaster ITP Registry: Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia 2014
Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial 2014
Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial 2014
Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data 2014
Transition of Care Under One Roof at the Mcmaster Hemoglobinopathy Clinic 2014
Utilization of Universal Group O Blood By Non Group O Recipients 2014
lLow Level Platelet-Activating Antibodies in Patients Suspected of Having Heparin-Induced Thrombocytopenia but Testing Negative in the "Gold Standard" Functional Test 2014
Making Decisions about Thromboprophylaxis in Pregnancy: Women’s Values and Preferences 2014
A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1 2013
A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12 2013
A Review Of Computed Tomography Pulmonary Angiograms In Three Teaching Hospitals: The Rise Of Sub-Segmental Pulmonary Emboli and Their Management 2013
A Zebrafish Model Of Antithrombin III Deficiency Displays Bleeding and Thrombosis Secondary To Disseminated Intravascular Coagulation 2013
Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up 2013
Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting 2013
Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM) 2013
Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model 2013
Characterization of Pulmonary Compliance in Sickle Cell Patients Revealed Wide Variability 2013
Combination Of 4T’s Score and Rapid Gel Centrifugation Assay Excludes HIT In a Prospective Cohort Study 2013
Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada 2013
Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients 2013
Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients 2013
Evaluation Of The Appropriateness Of Frozen Plasma Usage In The Era Of Prothrombin Complex Concentrates: A Retrospective Study 2013
Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality 2013
Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study 2013
Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II 2013
Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II 2013
Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II 2013
Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II 2013
Influenza Virus-Containing Immune Complexes Activate Platelets Through FcγRIIa Resulting In Bioactive Lipid Synthesis and Microparticle Release 2013
Long Term Treatment and Prevention Of Recurrent VTE In Cancer Patients: Results Of The Canadian Proact Survey 2013
Multiclonality In Multiple Myeloma: A Retrospective Analysis Of Clonal Progression and Selection 2013
Non-Invasive Hemoglobin Measurements In Anemic Patients 2013
Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study 2013
Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML) 2013
Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial 2013
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) 2013
Quebec Platelet Disorder Is Associated With Greater Than Expected Increases In Urokinase Plasminogen Activator In Granulocytes and Monocytes 2013
Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL 2013
Rituximab For The Treatment Of Hepatitis C Associated IgM Mediated Cold Hemolytic Anemia – Case Report and Literature Review 2013
Rivaroxaban Versus Low Molecular Weight Heparin For The Prevention Of Venous Thromboembolism After Orthopedic Surgery: A Population-Based Study 2013
Systematic Review and Meta-Analysis Of Rituximab For The Treatment Of Immune Thrombocytopenia In Adults 2013
The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial 2013
Transfusion Related Alloimmunization In Children: Epidemiology and Effects Of Chemotherapy (TRACE-EC Study) 2013
Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care 2013
A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial 2012
A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The SOX Trial 2012
A Systematic Review Evaluating the Effects of Treatment Duration on Bleeding Due to Factor-specific Oral Anticoagulant Therapy 2012
An in-Vitro Model Using Thromboelastography to Evaluate the Effects of Anticoagulants On Clot Formation in Plasma Enriched with Autologous Platelets 2012
Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry 2012
Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry 2012
Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up 2012
Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS 2012
Combination of Dexamethasone and Asparaginase Induces Prothrombotic State in Children Receiving Multiagent Chemotherapy for Acute Lymphoblastic Leukemia 2012
Comparative Cellular Studies of the VWF Exon 4–5 Deletion Mutation Using Patient-Derived Blood Outgrowth Endothelial Cells (BOEC) and Megakaryocytes 2012
Elevated Risk of Venous but Not Arterial Thrombosis in Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma 2012
First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis 2012
Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12 2012
Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life 2012
Higher Proportions of IFNg-Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial 2012
Inhibition of Platelet-Prothrombianse by a Covalent Antithrombin-Heparin Complex. 2012
Interactions of Heparin and a Covalently Linked Antithrombin Heparin Complex with the Components of the Fibrinolytic Pathway. 2012
Kruppel-Like Factor, Klf9, Promotes Proliferation of Notch-Independent Precursor T-Cell Lymphoblastic Lymphomas 2012
Management and Outcomes of Major Bleeding On Dabigatran or Warfarin 2012
Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes 2012
Partial in Vivo FVIII Stabilization by VWF Fragments 2012
Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial 2012
Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial 2012
Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis. 2012
Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study 2012
Reporting Bleeding Outcomes in Adult and Pediatric Studies of Primary Immune Thrombocytopenia: A Systematic Review 2012
Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies 2012
Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies 2012
Severe Impairment of γ-Globin Gene Silencing in an Asymptomatic Adult Patient Homozygous for the Codon 8 (–AA) Frame-Shift β0-Thalassemia Mutation 2012
The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation 2012
The Aryl Hydrocarbon Receptor (AhR) Regulates the Production of Bipotential Hematopoietic Progenitor Cells 2012
Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism 2012
Use of Intravenous Immune Globulin in Patients with Immune Thrombocytopenia Before and After Romiplostim: Real-World Experience 2012
A Functional In Vivo RNAi screen Involving Jumonji C Domain Containing Candidates Unravels Kdm5b As a Negative Modulator of Hematopoietic Stem Cell Self-Renewal 2011
A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II) 2011
An Approach for Tailoring Diverse Therapeutic Inducers of Fetal Globin to Genetic Modifier Profiles 2011
Bone Marrow Specimens From Patients with Immune Thrombocytopenia (ITP) Demonstrate Increased Megakaryocyte-Bound IgG and Increased T-Helper Cells 2011
Characterization of the Binding Between the Polymeric Platelet Adhesive Proteins, Multimerin 1 and Von Willebrand Factor 2011
Co-Administration Therapy Modulates Immunity to FVIII In Hemophilia A Mice 2011
Co-Inheritance of Delta Thalassemia Might Contribute to the High Fetal Hemoglobin in Sickle Cell Anemia Patients with the Saudi-Indian Haplotype 2011
Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant 2011
Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study 2011
Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib 2011
Dysregulation of C10orf55 Expression in Megakaryocytic Cell Lineage From Quebec Platelet Disorder Individuals 2011
Exploring the Impact of Clinical Anticoagulants on Venous Thrombosis Stability Using a Novel Intravital Murine Model 2011
Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study 2011
Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6 2011
Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study 2011
Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests 2011
Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study 2011
Inhibition of Red Blood Cell-Prothrombinase by Heparin and a Covalent Antithrombin-Heparin Complex 2011
Interaction of Multimerin 1 with Collagens: Role in Platelet Adhesion 2011
Laboratory HIT Testing in Critically III Patients 2011
Lung Cancer Chemotherapy Agents Increase Procoagulant Activity In Vitro and In Vivo 2011
Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model 2011
Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model 2011
Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates 2011
Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL) 2011
Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients 2011
Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score 2011
Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01 2011
Relationship Between Subtherapeutic Warfarin Anticoagulation and the Development of Post Thrombotic Syndrome After a First Unprovoked Deep Vein Thrombosis: Results From the REVERSE Cohort Study 2011
Rofecoxib Does Not Appear to Increase the Risk of Venous Thromboembolism: A Systematic Review of the Literature 2011
Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials 2011
The Inappropriate Use of the SimpliRed D-Dimer Assay in the Diagnosis of Venous Thromboembolism 2011
Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO 2011
Venous Thromboembolism Validation Study of the IMPROVE Risk Assessment Models in the Medical Patient (VTE-VALOURR) 2011
A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis 2010
A Predictive Model for the Development of High-Responding Inhibitor In Children. with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study 2010
A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia 2010
A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial 2010
Characterization of HbF Decline In Compound Heterozygotes for HbS and Deletional Hereditary Persistence of Fetal Hemoglobin. 2010
Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients 2010
Combinations of Epigenetic Modifying Agents Accentuate Retinoid-Mediated Gene Expression Over Single Agent Therapies In Acute Myelogenous Leukemia Cells. 2010
Competition In Engraftment of Normal Hematopoietic Stem Cells and Leukemic Stem Cells 2010
Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells 2010
Enriched MicroRNA-126 Bioactivity Marks the Primitive Compartment In AML and Regulates LSC Numbers 2010
Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of Saudi Patients From the Eastern Province. 2010
Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of Saudi Patients From the Southwestern Province. 2010
Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of the High Fetal Hemoglobin Phenotype In African American Patients. 2010
Functional Role of BAALC In Leukemogenesis 2010
Functional Role of BAALC In Leukemogenesis 2010
Gpx3 Determines Competitiveness of Normal and Leukemic Stem Cells 2010
Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level. 2010
Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies] 2010
Investigating the Experiences and Educational Needs of Adolescents with Hemophilia Prior to Transition of Care: A Website Development Project. 2010
Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia 2010
Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia 2010
Patterns of Management and Adherence to Venous Thromboembolism (VTE) Treatment Guidelines In a National Prospective Cohort Study of VTE Management In the Canadian Outpatient Setting: Recovery Study 2010
Plasma Fibronectin In Thrombosis and Hemostasis: Exploring the Fibrin Dependent and Independent Mechanisms 2010
Prothrombin Complex Concentrate (Octaplex (R)) In Patients Requiring Immediate Reversal of Vitamin K Antagonist Anticoagulation 2010
Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells 2010
Re-Expression of the AML1/ETO Target Gene LAT2/NTAL/LAB Results In Direct Interference with Myeloid Differentiation In AML1/ETO-Positive Cells 2010
SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature 2010
Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools 2010
The Role of Amino Acids 700-701 of the Factor Va Heavy Chain During Prothrombin Activation by Factor Xa. 2010
The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery 2010
The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia 2010
Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study 2010
Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism 2010
Variability In Hb A2 levels among Individuals with Beta-Thalassemia Trait: Is Iron Deficiency Associated with Abnormally Low Hb A2? 2010
Systematic Review of Pharmacologic and Compression Therapies for Treatment of Post-Thrombotic Syndrome 2010
A Cohort Study of Warfarin Administered to Achieve An INR of 2.0 to 3.0 for the Prevention of Recurrent Venous Thrombosis in Patients with An Antiphospholipid Antibody 2009
A Meta-Analysis of Randomized Controlled Trials of Aspirin in Primary Prevention of Cardiovascular Disease. 2009
A Multifaceted Strategy to Reduce Inappropriate Use of Fresh Frozen Plasma Transfusions in the Intensive Care Unit. 2009
A Potent Stimulator of Self-Renewal in Combination with MEIS1 Overexpression Allows the Transformation of Late Committed Myeloid Progenitors 2009
A Potent Stimulator of Self-Renewal in Combination with MEIS1 Overexpression Allows the Transformation of Late Committed Myeloid Progenitors. 2009
Adherence with Injectibal Prophylaxis for Venous Thromboembolism (VTE) Following Total Hip (THR) and Total Knee (TKR) Replacement Surgery: Complete Registry 2009
Adjudicating Bleeding Outcomes in a Large Thromboprophylaxis Trial in Critical Illness 2009
An RNA Interference Screen Identifies the Cell Fate Determinants Msi2 and Prox1 as Novel Regulators of Hematopoietic Stem Cell Self-Renewal 2009
Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study 2009
Covalent Antithrombin-Heparin Complex Catalysis of Activated Protein C Inhibition by Protein C Inhibitor 2009
Critical Values in the Coagulation Laboratory: Results of a Survey of the North American Specialized Coagulation Laboratory Association 2009
Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism 2009
Diagnostic Utility of Platelet Secretion Testing by ATP Release Assays: Results From a Prospective Study of Individuals Referred for Bleeding Disorder Assessments. 2009
Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia. 2009
Distribution and Clinical Signs of Venous, Arterial and Intracardiac Clots After Pediatric Cardiac Surgery 2009
Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy 2009
Extended Follow-up of the Multi-Center Multi-National Prospective Cohort Study That Derived the "Men Continue and HERDOO2" Clinical Decision Rule Which Identifies Low Risk Patients Who May Be Able to Discontinue Oral Anticoagulants (Oac) 5-7 Months After Treatment for Unprovoked Venous Thromboembolism (VTE). 2009
Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease. 2009
Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration 2009
High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Primary Therapy of Advanced Follicular Lymphoma in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 2009
Histone Demethylases as Modulators of Hematopoietic Cell Fate 2009
Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies 2009
Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation. 2009
Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically III Patients 2009
Investigation Into Mechanisms of Prothrombinase Complex Inhibition by a Covalent Antithrombin-Heparin Complex 2009
Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients 2009
Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin-in Patients with Immune Thrombocytopenic Purpura 2009
Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. 2009
Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors 2009
Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. 2009
Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban 2009
Quantitative Benefit-Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism. 2009
Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature 2009
Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis 2009
Targeted Gene Sequencing to Identify Polymorphisms in the Protein C and EPCR Genes in Patients with Unprovoked Venous Thromboembolism. 2009
Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia 2009
The Prevalence of Anti-Factor VIII Antibodies in the Hemophilia A Population of the Quebec Province of Canada: Results of Testing with the Bethesda/Nijmegen Assay and with Three ELISA Assays. 2009
The Quality and Accuracy of Hemophilia Information on the Internet 2009
The Role of Lysine Residues 42, 43, and 44 in the Activation Peptide Region of TAFI in Its Activation by the Thrombin-Thrombomodulin Complex 2009
Treatment of Hodgkin Lymphoma without G-CSF Does Not Increase the Risk of Febrile Neutropenia 2009
Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease 2009
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding 2008
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications 2008
Age-Related Differences in the Glycosylation of Anticoagulant Protein 2008
Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients 2008
An RNA Interference Screen Reveals Fate Determinants Implicated in Asymmetric Cell Division as Potential Regulators of Hematopoietic Stem Cell Self-Renewal. 2008
Autoantibodies in Patients with ITP Do Not Bind to Patient-Specific Epitopes on Platelet Glycoproteins 2008
C57BL/6JOlaHsd Mice with Tandem Deletion of the Multimerin 1and Alpha-Synuclein Genes Have Impaired Platelet Function in Vivo and in Vitro That Can Be Corrected by Multimerin 1 2008
Circulating Blasts Are Associated with High Levels of vWF and Thrombin Activation in Children with Newly Diagnosed ALL 2008
Fetal Hemoglobin in Sickle Cell Anemia: A Novel Method for High-Resolution Discovery of Associated Genomic Copy Number Variations 2008
High Levels of MicroRNA-126 Bioactivity Specify the LSC Compartment in AML 2008
Long Term Responses to Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia 2008
Monocyte-Derived Microparticles Improve Hemostasis in Factor VIII-Deficient Mice: Exploring the Role of PSGL-1/P-Selectin 2008
Natural History of Mesenteric Venous Thrombosis: A Large Multicentre Study 2008
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4 2008
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial. 2008
Predictors of Osteopenia/Osteoporosis in Children with Acute Lymphoblastic Leukemia 2008
Prospective Evaluation of An Argatroban Dosing Nomogram Using the Ecarin Chromogenic Assay at a Tertiary Institution 2008
Quebec Platelet Disorder Is Caused by a Cis-Acting Mutation near the Plasminogen Activator Gene (PLAU) That Increases PLAU Transcription by Megakaryocytes 2008
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation 2008
The Efficacy of H. pylori Eradication Therapy in H. pylori-Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review 2008
The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely III Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study 2008
The Impact of Deep Vein Thrombosis on Outcomes in Critically III Patients: A Systematic Review and Meta-Analysis 2008
The Unmet Need for Extended Thromboprophylaxis in Acutely III Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM 2008
Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature 2008
Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study 2008
A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. 2007
A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over. 2007
A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML). 2007
A Pilot Study of the Accuracy of Diagnostic Coding for Venous Thromboembolism within an Administrative Dataset of Emergency Department Visits. 2007
A negative D-dimer excludes recurrent deep vein thrombosis: Results of a multicentre management study. 2007
ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma. 2007
An individual platelet count set-point in ITP: A concept learned from patients with mild thrombocytopenia and a good response to IVIg or corticosteroids 2007
Bone marrow tells from patients with Shwachman-Diamond syndrome abnormally express ribosomal protein and ribosomal biogenesis-related genes 2007
Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study. 2007
Dalteparin Thromboprophylaxis in Critically Ill Patients with Severe Renal Insufficiency: The Direct Study. 2007
Epigenetic Repression of the Adaptor Molecule LAT2 by the Leukemic Fusion Protein AML1/ETO. 2007
Extended-duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: An evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint 2007
Factor Va Cofactor Activity Is Dependent on the Interaction of Prothrombin with the Membrane Surface. 2007
Fibrinolytic Agents for Restoration of Central Venous Catheter Patency: A Systematic Review. 2007
Gender differences in bleeding problems and implications for the assessment of a bleeding disorder 2007
Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years. 2007
Impact of Inherited Thrombophilia on Symptomatic Venous Thrombo-Embolism (VTE) in Children: A Systematic Review & Meta-Analysis of 37 Studies Including 2470 Pediatric Patients. 2007
Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia. 2007
Inhibition of the thrombin-thrombomodulin by a covalent antithrombin heparin 2007
Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement. 2007
Peripartum Management of Women with Suspected Hereditary Thrombocytopenia. 2007
Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: Toxicity data from the NCIC CTG MY.11 trial 2007
Proteomics in the study of qualitative platelet defects: Validation of the approach in the gray platelet syndrome and Quebec Platelet Disorder 2007
Risk factors predisposing to thromboembolism in children with cancer 2007
Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial. 2007
The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study. 2007
Treatment decisions for young women with supra-diaphragmatic, limited-stage Hodgkin lymphoma: Exploration of options using a Markov decision analysis. 2007
Understanding the Factor Va Cofactor Effect within Prothrombinase. 2007
Zinc enhances the protection of fibrin-bound thrombin from antithrombin inhibition 2007
A Multicentre Trial of the Effectiveness of ζ Globin Enzyme Linked Immunosorbent Assay (ELISA) and Hb H Inclusion Body Screening for the Detection of α Thalassemia Trait. 2006
A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma. 2006
An algorithm for "indeterminate" test results in the platelet serotonin release assay for heparin-induced thrombocytopenia (HIT). 2006
Atorvastatin Reduced Platelet Accumulation in Arteriolar Thrombi and Increases Platelet S-Nitrosylated N-Ethylmaleimide-Sensitive Factor. 2006
Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL). 2006
Controlling the Pathway for Prothrombin Activation by Prothrombinase. 2006
Cyclosporine-Induced Nephrotoxicity and Dose Adjustments in Bone Marrow Transplantation. 2006
Deficiency in TDAG51 Decreases Atherosclerotic Lesion Development in ApoE-Deficient Mice. 2006
Effects of Multimerin 1 on Platelet and Plasma FV as Determined by Calibrated Automated Thrombography. 2006
Efficacy of prothrombin complex (PCC) for reversal of warfarin effect. 2006
Endogenous Arteriolar Fibrinolysis Requires Urokinase Plasminogen Activator and Leukocyte Urokinase Plasminogen Activator Receptor-1. 2006
Evaluation of a VENOus-Return assist device (Venowave (TM)) to treat severe post-thrombotic syndrome (VENOPTS): A randomized controlled trial. 2006
Evaluation of the CapillaryS 2 CE System for Hemoglobinopathy Investigations. 2006
Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains. 2006
Fondiparinux Worsens Leukocyte Endothelial Interactions Improved by Antithrombin and Increases Leukocyte Extravasation. 2006
Implications of Heparinoid-Induced Inactivation of Coagulation Cascade Factors and In Vivo Proenzyme Concentration. 2006
Inhibition of Factor Xa in Prothrombinase Is Enhanced by Covalent Linkage of Antithrombin to Heparin. 2006
Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia. 2006
Long-Term Follow-Up of Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. 2006
No evidence for t(14;18)-positive cells in newborns and young children until the age of 10 followed by a linear increase of the prevalence in healthy individuals until the age of 50 years. 2006
Phospholipid components of the activated platelet surface determine multimerin 1 and factor V/Va binding, and modulate thrombin generation in plasma. 2006
Platelet-activating anti-platelet factor 4/polyanion antibodies without preceding heparin therapy: A transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT"). 2006
Predictors of Blood Transfusion Requirements in Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. 2006
Role of Gender in the Clinical Presentation of a First Deep Venous Thrombosis (DVT) in Outpatients. 2006
Safety and efficacy of anti-fibrinolytics in orthopedic surgery: A meta analysis of randomized trials. 2006
TDAG51 Deficiency Promotes Migration and Proliferation of Mouse Embryonic Fibroblasts. 2006
The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies. 2006
The management of anticoagulated patients requiring dental extraction: A cross-sectional survey of oral surgeons and hematologists. 2006
Transmission of Chromosomally Integrated HHV6 by Allogeneic Peripheral Blood Stem Cell Transplantation Associated with the Development of a Fatal Macrophage Activation (Haemophagocytic) Syndrome. 2006
Unexpected harmful side effects triggered by immune modulation. 2006
Unrelated Donor Umbilical Cord Blood Transplant Following Intrauterine Transfusions for Treatment of Alpha Thalassemia Major. 2006
Urokinase-type plasminogen activator production by cultured megakaryocytes and blood outgrowth enclothelial cells in the Quebec platelet disorder. 2006
Use of therapeutic dose low molecular weight heparin in patients with renal insufficiency: Analysis of anti-Xa levels and creatinine clearance. 2006
alpha 4-integrin(+) endothelium derived from primate embryonic stem cells generates both primitive and definitive hematopoietic cells. 2006
A Novel Inherited Platelet Function Disorder Involving the Thromboxane A2 Pathway of Platelet Activation. 2005
A Novel Thrombin Fluorogenic Substrate of High Affinity, Catalytic Efficiency and Selectivity. 2005
A multicenter, randomized, controlled clinical pilot trial of the feasibility of an intensive RBC transfusion policy for patients with acute leukemia treated with induction chemotherapy or stem cell transplant. 2005
A new model for predicting venesection therapy requirements in hereditary hemochromatosis using non-invasive liver iron concentration measurement 2005
A prospective cohort study of the epidemiology of symptomatic venous thromboembolism (VTE) after isolated leg fractures distal to the knee without thromboprophylaxis. 2005
A revisit of the criteria to define remission in patients with idiopathic thrombocytopenia undergoing splenectomy. 2005
Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. 2005
Age significantly influences presentation and patterns of care in patients with newly diagnosed diffuse large cell lymphoma (DLCL): Collective data from 5 centers participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. 2005
Anti-Xa levels and renal function: Analysis of the first 32 patients in the tinzaparin in renal insufficiency for venous thromboembolism study 2005
Anticoagulant Heparan Sulfate Mediates Antithrombin Amelioration of Leukocyte-Endothelial Interactions in Sepsis. 2005
Does thromboprophylaxis reduce mortality in medical patients? A systematic review and meta-analysis of randomized controlled tials 2005
Existing warfarin therapy in long-term care facilities maybe inadequate 2005
Exposure of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII. 2005
Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: The randomized APOLLO study. 2005
Insights into Disturbed Hemostasis in the Quebec Platelet Disorder Using Thromboelastography, Blood Clots Formed at Low Shear, and Perfusion Studies of Fibrinolysis. 2005
Intravenous gamma globulin does not increase RNA of FcgRIIb in purified human monocytes. 2005
Leukemia-related gene expression of bone marrow cells from patients with Shwachman-Diamond syndrome at the pre-leukemic phase. 2005
Low molecular weight heparin and bleeding in patients with severe renal failure: A meta-analysis 2005
Maintenance therapy with thalidomide/prednisone post autologous stem-cell transplant for patients with multiple myeloma elevates D-dimer and possibly factor VIII levels. 2005
Mechanisms of static and shear-induced platelet adhesion: Differences in the adhesion supported by MMRN1 comparisons with other beta 3 integrin ligands. 2005
MicroRNA Expression Profiling in Sorted AML Subpopulations: A Possible Role for miR-155/BIC in Stem Cell Maintenance and Leukemogenesis. 2005
Notch Activation Converts B Cells into a T Cell Fate at the Earliest Stages of B Cell Committed Progenitors. 2005
Outcomes of previously untreated older patients with multiple myeloma (MM) over time: An analysis of 3 consecutive trials conducted by the NCICCTG, 1983-2003. 2005
Patient Characteristics in CD 20+ and CD 20− Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis. 2005
PedsQL (TM) and EuroQol most responsive measures to change in health-related quality of life in children with Hodgkin's disease. 2005
Pitfalls in interpreting platelet function tests in thrombocytopenic patients referred by a hematologist for diagnostic testing: Results from a single center prospective study. 2005
Potential Impact of Pathologic Review on Therapy in Non-Hodgkin’s Lymphoma (NHL): Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. 2005
Potential impact of pathologic review on therapy in non-Hodgkin's lymphoma (NHL): Analysis from the national comprehensive cancer network (NCCN) NHL outcomes project 2005
Pregnancy in thalassemia patients and their partners in a Canadian population. 2005
Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM). 2005
Quantitiative Analysis of Roughness of Catheters by Scanning Electron Microscopy (SEM) and Atomic Force Microscopy (AFM). 2005
Rates of clinically apparent venous thromboembolism and death resulting from pulmonary embolism among unselected hospitalized acutely ill medical patients versus rates predicted from clinical studies. 2005
Relapse patterns and subsequent outcomes of patients treated on the NCICCTG HD.6 (ECOG JHD06) randomized trial evaluating ABVD alone in patients with limited stage Hodgkin lymphoma (HL). 2005
Rituximab for the treatment of adults with ITP: A systematic review 2005
Sequential analysis of the alpha- and beta-globin gene expressions during erythropoietic differentiation from primate ES cells. 2005
Should high-risk patients with chronic atrial fibrillation and those with coronary artery disease receive combined aspirin-oral anticoagulant therapy or oral anticoagulant therapy alone? A systematic review and meta-analysis 2005
Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia. 2005
The HPA-15 (Gov) Platelet Alloantigen System: Allele Frequencies in the Canadian Population. 2005
The Worcester Venous Thromboembolism Study: A Population Based Perspective of Venous Thromboembolism Attack Rates. 2005
Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin. 2005
Thromboembolism in children with sarcoma. 2005
Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor:: Pooled results of two phase Iib clinical trials. 2005
Towards a conceptual framework for diagnosis of heparin-induced thrombocytopenia (HIT) 2005
Trends in AIDS-Associated Cancers among Patients Attending a Palliative Care Service in Uganda in the ’Pre-HAART’ Era, 1994–2002. 2005
Undetected factor VIII level in a type III von Willebrand disease (vWD) patient masquerading as severe hemophilia 2005
Upper Extremity Deep Vein Thrombosis - Incidence, Risk Factors, and Management. The Worcester Venous Thromboembolism Study. 2005
Use of low dose oral vitamin K in the treatment of patients with INR values of more than 10.0. 2005
VENUS - A study to validate centrally adjudicated venous ultrasound against venography after major orthopaedic surgery. 2005
Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients with Heart Failure (NYHA Class III or IV): Findings from IMPROVE. 2005
Zinc2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes. 2005
A Prospective Registry on Venous Thromboembolic Events: Findings from PROVE. 2004
A Randomised Controlled Trail of Plasma Exchange in Rapidly Progressive Renal Failure of Myeloma. 2004
A Ten Year Survey of Chronic Immune Thrombocytopenic Purpura in Canadian Children, 1984–2003: Report of the Canadian Chronic ITP Working Group. 2004
A mutation in a GATA-1 binding site 5 ' to the (G)gamma-globin gene (nt-567, T > G) may be associated with increased levels of fetal hemoglobin. 2004
A phase II study of ZD6474, a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with relapsed multiple myeloma (MM). 2004
A prospective cohort study of the epidemiology of symptomatic venous thromboembolism (VTE) after isolated leg fractures distal to the knee without thromboprophylaxis. 2004
AML1/ETO Expresssion in Myeloid Leukemia Cells Is Associated with Enhanced Growth-Inhibitory and P15/INK4b Demethylating Effects of 5-AZA-2′-Deoxycytidine. 2004
AML1/ETO expression in myeloid leukemia cells is associated with enhanced growth-inhibitory and P15/INK4b demethylating effects of 5-aza-2 '-deoxycytidine. 2004
An Attempt to Reach Consensus Regarding Management of Neonatal Renal Vein Thrombosis: The Canadian Pediatric Hemostasis and Thrombosis Network Experience. 2004
Analysis of dosing variability of IVIG in community and teaching hospitals 2004
Analysis of the inflammatory and hemostatic changes and their relation to outcomes in an experimental model of heatstroke in baboons. 2004
Anti-Xa levels in critically ill patients receiving dalteparin for thromboprophylaxis. 2004
Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM) 2004
Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR. 2004
Atorvastatin Inhibits Leukocyte Firm Adhesion to Arterial Thrombi as Observed in the Mouse Cremaster Muscle. 2004
Benefit of fondaparinux in medical patients: A subgroup analysis. 2004
Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: Results from the REGIMEN registry. 2004
Cofactor Directed Catalysis. 2004
Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia. 2004
Comparison of compression ultrasound vs ascending contrast venography for proximal DVT in medical-surgical ICU patients. 2004
Continuous Versus Subsampling Analysis of Thrombin Generation. 2004
D-Dimer Assay during Menstrual Period. 2004
Effect of Covalently-Bound Heparin on Insertion of the Reactive Centre Loop in Antithrombin. 2004
Enoxaparin Is Effective and Safe as Bridging Anticoagulation in Patients with a Mechanical Prosthetic Heart Valve who Require Temporary Interruption of Warfarin because of Surgery or an Invasive Procedure. 2004
Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. 2004
Factors affecting physicians' decisions to transfuse red blood cells to patients having coronary artery bypass graft surgery: A national survey. 2004
Fixed-Dose, Weight-Adjusted, Unfractionated Heparin (UFH) Given Subcutaneously (sc) without Laboratory Monitoring for Acute Treatment of Venous Thromboembolism (VTE): Randomized Comparison with Low-Molecular-Weight-Heparin (LMWH). 2004
Human Platelets Contain Forms of Factor V in Disulfide-Linkage with Multimerin. 2004
Identification and Characterization of Hemoangiogenic Progenitors during Cynomolgus Monkey ES Cell Differentiation. 2004
Identification of Medical Patients Who Should Receive Venous Thromboembolism Prophylaxis. 2004
Identification of the multimerin binding region within the C2 domain of human factor V using constructs generated by alanine-scanning and site-directed mutagenesis. 2004
Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data. 2004
Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: P53-Independent Upregulation of P21/WAF/CIP1. 2004
Induction of G1 arrest and apoptosis in a conditional expression model of AML1/ETO: p53-independent upregulation of p21/WAF/CIP1 2004
Inhibition of factor Xa in prothrombinase is enhanced by covalent linkage of antithrombin to heparin 2004
Laboratory testing for HIT antibodies: How much class do we need? 2004
Newly diagnosed follicular (FL), mantle cell (MCL), and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in 5 United States comprehensive cancer centers: An analysis from the national comprehensive cancer network (NCCN) NHL outcomes project. 2004
No fibrinolytic benefit of adjunctive anticoagulation during arterial thrombolysis induced by tPA combined with TAFIa inhibitor in a rabbit arterial thrombosis model. 2004
Non-ablative or reduced intensity conditioning regimens with volunteer unrelated donor progenitor cell transplantation. 2004
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT): A Pilot Study. 2004
Perioperative Bridging Therapy with Enoxaparin in Patients Requiring Interruption of Long-Term Oral Anticoagulant Therapy: A Multicenter Cohort Study. 2004
Phase II Trial of Bortezomib in Mantle Cell Lymphoma. 2004
Platelet Transfusions in a Medical- Surgical Intensive Care Unit. 2004
Prevalence and Incidence of Arterial and Venous Thrombosis in Critically Ill Patients. 2004
Prospective Cohort Study of the Incidence, Risk Factors and Long-Term Sequelae of Symptomatic Catheter-Related Thrombosis in Adults with Cancer. 2004
Reaction of Fibrin-Bound Thrombin with a Covalent Antithrombin-Heparin Complex Results in an Anticoagulant Surface. 2004
Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant. 2004
Risk Factors for Bleeding in Patients with Nonvalvular Atrial Fibrillation Who Are Receiving Anticoagulant Therapy with Ximelagatran or Warfarin: Findings from the SPORTIF III and V Trials. 2004
Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA. 2004
Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin. 2004
Safety and Efficacy of Low Molecular Weight Heparins for Hemodialysis in Patients with End-Stage Renal Disease: A Meta-Analysis of Randomized Trials. 2004
Safety and efficacy of venous thromboembolism prophylaxis with low molecular weight heparin in hospitalised patients with acute medical illness and renal failure. 2004
Secretable Human Megakaryocyte Factor V Endocytosed from Plasma in Complex with Multimerin: The Origin of Human Megakaryocyte Factor V. 2004
Significant Differences in Neutralization of Heparin and Its Low Molecular Fragments by Protamine Sulfate: An In Vivo Study. 2004
Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa. 2004
Survival of HIV infected individuals with hemophilia after 20 years: From the Canadian Hemophilia Registry. 2004
The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review. 2004
The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous thromboembolism prophylaxis practices in acutely ill medical patients 2004
The Mechanism of Transfusion-Related Immunomodulation Is Related to the Transfusion of Dendritic Cells Expressing the CD200 (OX-2) Tolerance Signal and Alloantigen: Evidence from a Murine Tumor Model. 2004
The Proadhesive Properties of Multimerin in Supporting Cellular Adhesion: Evidence for RGD and Non-RGD Dependent Adhesive Mechanisms. 2004
The Safety of Co-Administered Low-Molecular-Weight Heparin and Continuous Epidural Analgesia after Major Orthopedic Surgery: Assessment of a Standardized Management Protocol. 2004
The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis. 2004
The risk of hemorrhage and the frequency of vitamin K use in asymptomatic patients with warfarin-associated coagulopathy. 2004
Triple Immunosuppressive Therapy in Patients with Chronic Resistant Immune Thrombocytopenic Purpura; a Case Series of 11 Patients. 2004
Use of Intravenous Immunoglobulin for Treatment of Neurological Conditions: A Systematic Review. 2004
Weekly cyclophosphamide and alternate day prednisone: An effective, convenient and well tolerated treatment for relapsed multiple myeloma following autologous stem cell transplant. 2004
Williams-Beuren Syndrome Critical Region-5/Non-T Cell Activation Linker: A Novel Target Gene of AML1/ETO. 2004
Williams-Beuren syndrome critical region-5/non-T cell activation linker: A novel target gene of AML1/ETO. 2004
Ximelagatran Versus Warfarin: A Comparison of Bleeding Outcomes in Patients with Nonvalvular Atrial Fibrillation. 2004
A paper-based warfarin algorithm for maintenance of anticoagulation within an INR range of 2.0 to 3.0 2003
A phase II study of Bortezomib in patients with mantle cell lymphoma 2003
A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06). 2003
A randomized trial in hemophilic patients comparing handheld computers with paper diaries for submission of coagulation factor concentrate infusion data. 2003
A retrospective study evaluating single unit red cell transfusions in reducing allogeneic blood exposure. 2003
Accelerated clearance of a recombinant human Factor IX protein lacking activation peptide residues 155-177. 2003
Analysis of the inhibition of prothrombin activation by recombinant mutant substrates that produce only meizothrombin or fragment 1.2 : prethrombin-2. 2003
Bleeding symptomatology associated with inheritance of the Quebec platelet disorder. 2003
Cofactor role of fibrin in stimulation of tissue-type plasminogen activation of Glu- and Mini-plasminogen. 2003
Comparison of heparin-induced thrombocytopenia antibody (HIT-Ab) generation and in vitro cross-reactivity after elective hip or knee replacement surgery in patients receiving Antithrombotic prophylaxis with fondaparinux or enoxaparin. 2003
Costs and benefits of on-demand and prophylactic treatment strategies for severe haemophilia. A health-economic evaluation. 2003
Demonstration of platelet engraftment by platelet genotyping after HPA-mismatched allogeneic peripheral blood transplantation 2003
Development of primitive and definitive hematopoiesis from nonhuman primate embryonic stem cells in vitro. 2003
Does low molecular weight heparin give a high aluminium load? 2003
Effect of fondaparinux on platelet activation in the presence of heparin-dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin. 2003
Effect of functional Heparin-PF4 antibodies from patients with heparin-induced thrombocytopenia on blood coagulation assessed by thrombelastography. 2003
Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. 2003
FIXa incorporated within intrinsic tenase is protected from inhibition by ATIII/heparin complex. 2003
Factors at baseline influencing the risk of recurrence in venous thromboembolism: Results of a meta-analysis on individual patient data. 2003
Fondaparinux for the prevention of VTE in acutely ill medical patients. 2003
Functional heparin-PF4 antibodies from patients with heparin-induced thrombocytopenia (HIT) cause platelet-monocyte aggregation: Implications for the pathogenesis of HIT. 2003
Ganciclovir prophylaxis is associated with delayed neutrophil engraftment in patients undergoing haploidentical transplantation. 2003
Homozygous inheritance of the Cys8Arg mutation in the amino-terminal region of platelet glycoprotein IX in a family with Bernard-Soulier syndrome. 2003
IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: A comparison with clinical study patient populations. 2003
Impaired thrombus growth and stability in vitro nectin deficient mice. 2003
Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells. 2003
Influence of age on the risk of recurrence in venous thromboembolism and on the risk of major hemorrhage during oral anticoagulant therapy: Results of a meta-analysis on individual patient data. 2003
Initial experience with yttrium 90 ibritumomab tiuxetan (Zevalin®):: A model for successful implementation of radioimmunotherapy (RIT) in the community setting. 2003
Localization of thrombin activity with self-quenching fluorogenic substrates during arterial thrombi formation in living mice. 2003
Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: A genetic predisposition. 2003
Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. 2003
Periprocedural anticoagulation for patients with mechnical heart valves: A survey of 324 clinicians. 2003
Periprocedural anticoagulation in patients with mechanical heart valves: An international survey of expert clinicians. 2003
Platelet-dependent dissolution of fibrin clots in the Quebec platelet disorder. 2003
Predictors of infection and bleeding in patients with chemotherapy induced thrombocytopenia 2003
Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: The "4 T's". 2003
Prevalence and predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis: Results from a randomized trial comparing two intensities of anticoagulation. 2003
Probing HUVEC granule compartments with recombinant fluorescent platelet factor 4: Evidence that Weibel-Palade bodies are not a default storage compartment. 2003
Prophylactic G-CSF and GM-CSF decrease febrile neutropenia following chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. 2003
Red blood cell transfusion practices in a teaching hospital intensive care unit - Has the TRICC trial changed our standard of care? 2003
Registry of patients on chronic oral anticoagulant therapy requiring (Low-Molecular-Weight) heparin for an elective surgical intervention or procedure (REGIMEN): Rationale, design, and interim analysis of a large, long-term, multicenter cohort study. 2003
Rituximab for indolent lymphoma: An analysis of outcomes in a large population-wide study. 2003
Selective eradication of acute myeloid leukemia stem cells using an antibody that ligates the CD44 adhesion molecule. 2003
Subclass analysis of Anti-Ib/IX autoantibodies in patients with idiopathic thrombocytopenic purpura. 2003
Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. 2003
The EXCLAIM study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. 2003
The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation 2003
The percentage of hemoglobin Barts as a predictor for the alpha thalassemia genotype in cord blood samples. 2003
Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada: Results from the Canadian Registry (CURVE). 2003
Variability of clinical laboratory practice in testing for disorders of platelet function: Results of a second NASCOLA survey. 2003
Venous ultrasound: An alternative to venography for evaluation of Dalteparin prophylaxis in 3,706 medically ill hospitalized patients. 2003
Video laparoscopic surgery: Is the out-of-hospital thromboprophylaxis necessary? 2003
A Randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE). 2002
A prospective study of clinical laboratory findings in patients referred by a hematologist for investigation of a suspected platelet disorder. 2002
A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. 2002
A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada clinical trials group study 2002
A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies. 2002
An assessment of APTT heparin therapeutic reference intervals in Ontario 2002
Analysis of fetal DNA present in maternal plasma, for the prenatal diagnostic work-up of fetuses at risk of inheriting beta-thalassemia major. 2002
Bleeding complications of thromboprophylaxis after hip replacement: A systematic review. 2002
Cardiobacterium hominis endocarditis masquerading as very severe refractory immune thrombocytopenic purpura: Report of a case. 2002
Case-fatality for major bleeding and intracranial hemorrhage in patients with venous thromboembolism on long-term oral anticoagulant therapy: A systematic review. 2002
Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia. 2002
Comparison of activated clotting time values between Hemochron signature and Hemochron 801. 2002
Control of plasma thrombin generation on fetal distal lung epithelium by covalent serpin-heparinoid complexes. 2002
Diagnosis of deep vein thrombosis during pregnancy: A pilot study evaluating the role of D-dimer and compression leg ultrasound during pregnancy. 2002
Dissociation of vWF-cleaving protease activity and platelet count in a patient with familial thrombotic thrombocytopenia purpura. 2002
Effect of age on the benefit-risk ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery. 2002
Effects of a novel venous-return assist device ("venowave") on lower limb venous flow in patients with post-thrombotic syndrome 2002
Efficacy of aspirin treatment in pediatric stroke patients as measured with the PFA-100. 2002
Elevated levels of D-dimer upon central venous catheter introduction identify patients at high risk of developing subclavian vein thrombosis. 2002
Evaluation of a directed donor transfusion program in the Neonatal Intensive Care Unit: Does directed donation reduce allogeneic exposures to neonates? 2002
Evidence of intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder. 2002
Experiences of continuous infusion of B-domain deleted recombinant factor VIII (ReFacto (R)) for major surgery. 2002
Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism:: A randomized, placebo-controlled trial. 2002
Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study. 2002
GH9001, a novel antithrombotic agent, is more effective than low-molecular-weight heparin or hirudin in rabbit models. 2002
Gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy for relapsed or refractory Hodgkin's disease (HD): A National Cancer Institute of Canada Clinical Trials Group Study. 2002
Gemcitabine, dexamethasone, cisplatin for relapsed or refractory non-Hodgkin's lymphoma (NHL): A National Cancer Institute of Canada Clinical Trials Group study. 2002
Gender and risk of immune heparin-induced thrombocytopenia (HIT). 2002
Genetic polymorphisms in the noncoding sequences of the PF4 and PF4alt genes are not associated with the development of heparin-induced thrombocytopenia. 2002
Heparin catalysis of factor IXa inhibition by antithrombin depends on both pentasaccharide-induced conformational changes in antithrombin and heparin-mediated bridging of antithrombin to factor IXa. 2002
Immunization to platelet alloantigens: A ten-year retrospective study. 2002
Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery. 2002
Inherited factor VII deficiency and thrombosis in relation to FVII genotype and thrombophilia. 2002
Interobserver agreement on ultrasound measurements of thrombus diameter and length: Derivation of criteria for the diagnosis of recurrent deep vein thrombosis. 2002
Kinetics of platelet activation, P-selectin expression and leukocyte rolling during arterial thrombus formation in vivo. 2002
Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. 2002
Low-intensity (INR 1.5-1.9) versus conventional-intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: A randomized double blind trial. 2002
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by Doppler ultrasound. 2002
Prophylactic growth factor use in older patients with previously untreated acute myeloid leukemia: A published data meta-analysis. 2002
Prospective Multicentre trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAC for prosthetic valves or high risk atrial fibrillation. 2002
Quality of life assessment for oncology patients: Assessing the clinical significance. 2002
Recombinant activated factor VII for massive hemorrhage in non-hemophilia patients: The Australian experience. 2002
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low molecular weight heparin following elective hip arthroplasty. A systematic review. 2002
Severe bleeding problems in patients with acquired delta-storage pool disorder (delta-SPD) due to myelodysplastic and myeloproliferative disorders. 2002
Successful dose adjusted replacement therapy in acquired factor XIII deficiency. 2002
The Influence of age on in vitro plasmin generation in the presence of fibrin monomer 2002
The mTOR inhibitors rapamycin and RAD001 are active in experimental models of ALL and are antagonized by interleukin-7. 2002
Ultrasound measurement of thrombus cross-sectional area instead of thrombus diameter: A better way to diagnose recurrent deep vein thrombosis. 2002
Variation of APTT EQA results obtained with various combinations of coagulation instruments and APTT reagents 2002
Venous thromboembolism risk assessment in medical patients. 2002
5-Aza-2 '-deoxycytidine (5-Aza-2-Cdr) reverses CpG methylation of the retinoic acid receptor beta (RAR beta) promoter and restores retinoid responsiveness in non M3 acute myelogenous leukemia (AML) blasts. 2001
A cure for murine sickle cell disease (SCD) through stable mixed chimerism and tolerance induction after non-myeloablative conditioning and MHC-mismatched bone marrow transplantation. 2001
A novel universal antigen capture assay to measure platelet-bound autoantibodies in immune thrombocytopenic purpura. 2001
Benefit of enoxaparin in medical patients. A subgroup analysis. 2001
Bone marrow derived dendritic cell vaccination of spontaneous canine melanoma using human gp100 antigen. Clinical and immunological findings. 2001
Both exosites on thrombin mediate its high affinity interaction with fibrin. 2001
Complete remission of acute promyelocytic leukemia with ATRA. 2001
Covalent antithrombin-heparin complex (ATH): An alternative to heparin for arterial thrombosis prevention. 2001
Current management of venous thromboembolism prophylaxis after major orthopedic surgery in North America and Europe: Lessons from the pentasaccharide (fondaparinux, Arixtra (R)) database. 2001
EBV detection in sequential biopsies from patients with recurrent acute allograft rejections and relationship to posttransplant lymphoproliferative disorder. 2001
Economic evaluation of the MEDENOX trial: A Canadian perspective. 2001
Effect of renal function on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zoledronic acid in cancer patients with bone metastases. 2001
Effect of splenectomy in patients with chronic idiopathic thrombocytopenic purpura. 2001
Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra (R)) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery. 2001
Efficacy of a novel IGIV preparation in the treatment of acute and chronic ITP. 2001
Evaluation of whole blood derived platelets stored as a pool. 2001
Four weeks versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE) provoked by a transient-risk factor: A randomized double-blind trial. 2001
Helper-dependent adenovirus delivery of a canine FVIIIB-domain deleted transgene in murine and canine models of hemophilia A. 2001
In vitro comparison of the effect of heparin, low-molecular-weight heparin and pentasaccharide on tests of coagulation. 2001
In vivo real time imaging of arterial thrombus formation reveals P-selectin- and PSGL-1-mediated tissue factor accumulation as a mechanism for fibrin clot generation. 2001
In vivo tracking of prospectively isolated CD34(+)Lin(-) and CD34(-)Lin(-) subsets reveals functional regulation among cells within the human stem cell compartment. 2001
Melagatran, the active form of the oral direct thrombin inhibitor ximelagatran - An alternative to hirudin in prevention of arterial thrombosis with a wider therapeutic window. 2001
Multimerin storage and processing by human megakaryocytes in culture. 2001
Patients with severe sepsis vary markedly in their ability to generate activated protein C. 2001
Pentasaccharide (fondaparinux, Arixtra (R)) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: Subgroup analyses on efficacy. 2001
Phase II study of repetitive mini-transplant using a novel dose-intense salvage chemotherapy regimen (M-DHAP) followed by high dose therapy (HDT) and autologous stem cell transplant (ASCT) in relapsed aggressive non-Hodgkin lymphoma (NHL). 2001
Platelet plasminogen contributes to u-PA dependent proteolysis of platelet alpha-granule proteins. Implications for the mechanism of stored platelet protein degradation in the Quebec Platelet Disorder. 2001
Relevance of systematic venographic outcomes in venous thromboembolism (VTE) prophylaxis studies: Lessons from the pentasaccharide (fondaparinux, Arixtra (R)) clinical program. 2001
Renal pathology in patients who died following hematopoietic stem cell transplantation. 2001
Risk factors for central venous catheter-associated thrombosis in patients with cancer. 2001
Rituximab in lymphoma: A review of a province-wide initiative after one year. 2001
Role of the B beta 1-42 sequence of fibrin(ogen) in plasminogen activation. 2001
Subclass distribution of platelet bound anti-GPIIbIIIa autoantibodies in immune thrombocytopenic purpura. 2001
Survival of patients with acute leukemia after bone marrow transplantation using allografts depleted of T-cells by counterflow centrifugal elutriation (CCE). 2001
THRIVE I: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. 2001
Ten-year follow-up of von Willebrand factor (vWF) multimers in two patients with bleeding gastrointestinal (GI) angiodysplasias and aortic stenosis with long-term cessation of bleeding following aortic valve replacement: A novel bleeding syndrome of surgically-reversible acquired von Willebrand's syndrome (vWS-2A). 2001
The lymphoma progenitor in E mu-RET/RFP transgenic, lymphoma-prone mice remains at the pro-B to pre-B cell stage after undergoing malignant transformation. 2001
The predictors of clinical outcome in patients with heparin-induced thrombocytopenia. 2001
Trafficking of autoantibodies in platelets from ITP patients: Investigation using glycoprotein-specific assays. 2001
Twice daily enoxaparin, but not once daily dalteparin, is associated with elevated anti-factor Xa heparin levels at the time of epidural catheter removal. 2001
Variable expression of platelet GPIb-IX-V subunits in a family with Bernard-Soulier Syndrome. 2001
A Canadian randomized study comparing peripheral blood (PB) and bone marrow (BM) in patients undergoing matched sibling transplants for myeloid malignancies. 2000
A comparison of the nonspecific binding of low molecular weight heparin during the three trimesters of pregnancy. 2000
A prospective cross-sectional study to characterize selected autoimmune (AI) markers and report the incidence of antithrombopoietin antibodies (alpha TPO) in patients with immune thrombocytopenic purpura (ITP). 2000
A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma. 2000
Absence of deferiprone-induced hepatic fibrosis: A multi-center study. 2000
Allogeneic bone marrow transplantation (allo BMT): Role of T cell depletion (TCD) and graft versus host disease (GVHD). 2000
Assessing pore formation by Bcl-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment. 2000
Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations? 2000
Comparison of post transfusion platelet response following random donor and apheresis platelets. 2000
Cytokine responsiveness of circulating human embryonic hematopoietic stem cells is unique compared to other stages of human ontogeny. 2000
Decreased von Willebrand factor proteolytic activity associated with thrombocytopenic disorders. 2000
Effectiveness of reconstituted and then frozen tPA for dysfunctional percutaneous dialysis catheters. 2000
Evaluation of platelet morphology and the subcellular distribution of PAIgG in patients with ITP and non-immune thrombocytopenia. 2000
Expression of CD109 with alternate forms of membrane anchoring unique to platelets and megakaryocytic cell lines. 2000
Factor V Leiden and arterial ischemic stroke in children: A meta-analysis. 2000
Fibrinogen gamma chain binds thrombin exosite II. 2000
Glycoprotein Ib and PSGL-1 serve as platelet ligands for platelet-endothelial cell interaction during platelet rolling on stimulated postcapillary venules in vivo. 2000
Hemochromatosis due to aceruloplasminemia: Treatment of an adult Caucasian. 2000
Human cord blood Lin-CD45-cells are capable of both hematopoietic and chondrocytic function. 2000
Human homologs of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. 2000
Hyperbilirubinemia secondary to gamma-irradiation of red cells. 2000
Identification of the fibrinolytic protease released by platelets in the Quebec platelet disorder. 2000
Identification of the mechanism responsible for the decreased fibrin specificity of reteplase relative to tissue-type plasminogen activator. 2000
Identification of vesicular stomatitis virus as a leukemolytic agent. 2000
IgG subclass evaluation of antibodies against specific platelet glycoprotein IIb/IIIa using antigen capture technique. 2000
In vitro time-dependent changes of surface PAIgG in ITP and non-immune thrombocytopenia. 2000
Incorporation of fragment X into clots increases their susceptibility to lysis. 2000
Induction of hematopoietic cell fate from neuronal and muscle cells in the human. 2000
Isolation of CD34-AC133+LIN- cells from the human stem cell compartment reveals superior retroviral transduction to that of CD34+CD38-LIN-. 2000
Laboratory screening for hemoglobinopathies in the province of Ontario: Proficiency and patterns of practice. 2000
Number of viable CD34+cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. 2000
Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes. 2000
Phase I-II trial of VACOP-B plus filgrastim (G-CSF) support for HIV-related non-Hodgkins lymphoma (NHL). 2000
Phospholipid micelles, but not vesicles, neutralize heparin: An explanation for the minimal effect of heparin on the prothrombin time. 2000
Population screening, molecular confirmation, and prevalence of hemoglobin H disease among newborns in California. 2000
Possible pathways of IgG trafficking in platelets. 2000
Prospective evaluation of early discharge of patients with chemotherapy-induced febrile neutropenia and hematological malignancies. 2000
Proteomic analysis of the beta-arrestin signaling complex in chemokine receptor signal transduction. 2000
Quantitative frequency analysis of human stem cells in ex vivo cultures reveals the existence of a pre-SCID repopulating cell (Pre-SRC). 2000
Response to sodium phenylbutuyrate and hydroxyurea in thalassemia: Possible effect of marrow expansion on augmentation of fetal hemoglobin (HbF). 2000
Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-Hodgkin's lymphoma. 2000
Sickle cell disease in a four year old child with apparent HbS trait. 2000
Site-directed mutagenesis at P6 in heparin cofactor II creates a thrombin-inhibitory serpin that is resistant to neutrophil elastase inactivation. 2000
Sulfate density of the low molecular weight heparins determine their protamine neutralizability. 2000
The human homologs of Sonic hedgehog induces proliferation of primitive human hematopoietic stem cells via regulation of BMP-4. 2000
The impact of idiopathic thrombocytopenic purpura in pregnancy. 2000
The notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells. 2000
Transience of heparin-induced thrombocytopenia antibodies. 2000
Treatment of chronic refractory idiopathic thrombocytopenic purpura with cyclophosphamide and cyclosporine. 2000
Treatment of excessive anticoagulation due to warfarin with oral vitamin K: A randomized controlled trial. 2000
Use of vitamin K to reverse warfarin-induced excessive anticoagulation: A survey of current practice habits. 2000
A dipstick assay for diagnosis of heparin-induced thrombocytopenia (HIT). 1999
A novel role for combined anti-angiogenesis therapy and immunotherapy: Treatment of a murine breast cancer model using adenoviral gene therapy vectors expressing angiostatin and interleukin-12. 1999
A phase I study of adenovirus engineered, interleukin 2 (IL-2) secreting, autologous plasma cell vaccination for the treatment of multiple myeloma. 1999
A randomized Canadian Bone Marrow Transplant Group study comparing peripheral blood and bone marrow allografts in patients undergoing matched sibling transplants for acute myeloid leukemia, chronic myeloid leukemia and myelodysplasia. 1999
A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets. 1999
Adenoviral-based gene transfer in a murine model of chronic lymphocytic leukemia. 1999
Alpha-thalassemia mutations detected by multiplex-PCR. 1999
An interim analysis to improve precision of warfarin anticoagulation control in a randomized clinical trial. 1999
Analysis of plasma thrombin activatable fibrinolysis inhibitor in a young population pre and post venous occlusion. 1999
Assessment of a xi-globin enzyme-linked immuno-sorbent assay (ELISA) for the detection of alpha-thalassemia trait. 1999
Biology of the hypercoagulable state following major trauma. 1999
Bone marrow versus peripheral blood allografts: An evaluation of the donor experience in a Canadian multicentre randomized trial. 1999
Calcium-dependent binding of heparin influences the catalytic activity of factor Xa. 1999
Cell cycle status of human fetal and cord blood cells capable of multilineage repopulation in NOD/SCID mice. 1999
Characterization of circulating human hematopoietic stem cells during in utero development. 1999
Decreased bone mineral density after autologous blood and marrow transplantation(ABMT). 1999
Dose finding and pharmacokinetics of prophylactic doses of a low molecular weight heparin (reviparin (TM)) in pediatric patients. 1999
Early loss of adhesion during apoptosis is independently regulated by BCL-2 and caspases. 1999
Ermap, A gene coding for a novel erythroid specific adhesion/receptor membrane protein. 1999
Evaluation of clot formation in AS-3 red cells diluted with Ringer's lactate. 1999
Fibrinolytic response to venous occlusion is reduced in children with Kawasaki disease or hyperlipidemia. 1999
Genetic modifiers of hemoglobinopathies 1999
Homocysteine enhances cholesterol biosynthesis in cultured human smooth muscle cells and hepatocytes. 1999
Impact of size-restricted diffusion of thbombin inhibitors into thrombi on the susceptibility of fibrin-bound thrombin to inactivation. 1999
In vitro assessment of hemostasis by the PFA-100 (TM): Direct comparison to bleeding in vivo in a rabbit ear bleeding model. 1999
In vivo purging with rituxan prior to stem cell collection is associated with persistant molecular evidence of T(14;18) that often disappears post transplant in patients with follicular lymphoma. 1999
Isolation of human stem cells capable of multilineage repopulation is not dependent on the level of CXCR4 expression. 1999
Low-grade lymphoma: A prospective multicenter evaluation of clinical and biologic prognostic factors. 1999
Morphological investigation of microparticle generation in heparin-induced throbocytopenia using confocal microscope and electron microscopy. 1999
Mortality reduction with low molecular weight heparin thromboprophylaxis in acutely ill medical patients: The MEDENOX trial. 1999
Optimum timing of apheresis following rHuGCSF and rmetHuSCF in multiple myeloma: A temporal analysis of CD34 absolute counts and subsets. 1999
Phase II study of topotecan plus etoposide in patients with aggressive histology non-Hodgkin's lymphoma (NHL). 1999
Platelets contain and secrete disulfide-linked polymers of coagulation factor V. 1999
Potential interaction of bivalirudin and heparin after interchange of these agents. 1999
Proteolysis of human platelet FcRIIa during activation induced by heparin-induced thrombocytopenia (HIT) sera. 1999
Receptor-mediated erythrocyte self-destruction. Evidence that increased membrane permeability to Na+ precedes hemolysis in-vitro. 1999
Role of hedgehog proteins in human hematopoietic stem cell development. 1999
Screening for silent globin gene mutations in areas with high prevalence of thalassaemia. 1999
Simplifying heparin monitoring. 1999
Stabilty and sterility of recombinant tissue plasminogen activator under-39 degrees C. 1999
Subclass restriction of autoantibodies in patients with idiopathic thrombocytopenic purpura. 1999
Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement. 1999
The effect of heparin on bone strength in mice. 1999
The expression of chemokine receptors on primitive human hematopoietic cells. 1999
The glycosylation site within kringle 1 modulates fibrin-specificity of TNK-t-PA. 1999
The preferences of traditional quality of life domains are similar in older versus younger patients with non-Hodgkin's lymphoma. 1999
The prevalence of positive soluble fibrin and D-DIMER results in healthy asymptomatic pregnant women. 1999
The safety and efficacy of a TAFIa inhibitor ln a rabbit arterial thrombolysis and bleeding model. 1999
The use of low dose warfarin for prophylaxis of catheter-related thrombosis in cancer patients. 1999
Thrombin and neutrophil elastase react with a truncated, his-tagged recombinant heparin cofactor II derivative with seven reactive centre loop residue substitutions at P-6. 1999
Use of tissue plasminogen activator to clear blocked central venous lines in pediatric patients: A prospective cohort study. 1999
Venous limb gangrene (VLG) complicating warfarin treatment of deep-vein thrombosis (DVT) ln metastatic carcinoma. 1999
'Incidental' unfractionated heparin (UFH) vs normal saline (NS) flushes for intraoperative invasive catheters and the frequency of formation of heparin-induced thrombocytopenia IgG antibodies (HIT-IgG): A randomized, controlled trial. 1998
Abnormal fibrinolysis does not predispose to first or recurrent thromboembolism. 1998
Analysis of engraftment in a randomized trial of 4hydroperoxycyclophosphamide (4HC) purged autologous bone marrow transplant (ABMT) in patients with lymphoid malignancies: Preliminary analysis of engraftment. 1998
Autologous bone marrow transplantation (ABMT) with 4-hydroperoxycyclophosphamide (4HC) purging as treatment for indolent non-Hodgkins lymphoma (NHL). 1998
Both activation and active site occupation of human factor VII alter conformation of the first EGF-life domain. 1998
CD34+ t(15;17) APL represents a distinct subgroup associated with CD2+, bcr3 isoform, microgranular morphology, a high white count and a poor prognosis. 1998
Comparing the in vitro response to heparin in non pregnant and pregnant women. 1998
Comparison of the clinical utility of the platelet function analyzer (PFA-100 (TM)) and standard bleeding time in patients with hemostatic disorders. 1998
Covalent heparin cofactor II heparin and heparin cofactor II dermatan sulfate complexes: Characterization of novel anticoagulants 1998
Diagnostic accuracy of SimpliFED (R) D-dimer testing in cancer patients with clinically suspected deep vein thrombosis. 1998
Effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. 1998
Extended out-of-hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. 1998
Fludarabine and cyclophosphamide: A highly active and well tolerated regimen for patients with previously untreated indolent lymphomas. 1998
Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): Evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors. 1998
Heparin-induced bone loss is not reversible after stopping heparin treatment in rats. 1998
In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHM. 1998
Inhibition of angiogenesis in a fibrin matrix by abciximab. 1998
Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex. 1998
Loss of CD34(+)/CD38(-) cells during ex vivo expansion of purified CD34(+) stem cells using adenoviral-based gene transfer of stem cell factor to bone marrow stromal cells. 1998
Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate, but not heparin. 1998
Outpatient autologous hematopoietic stem cell (HSCT) transplantation following short course VAD in multiple myeloma. 1998
Partial purification and characterization of serine protease activity in platelets and platelet releasates from patients with Quebec platelet disorder 1998
Phospholipase digestion and detergent solubility define two distinct populations of platelet CD109. 1998
Preparative regimens in bone marrow transplantation: An analysis of outcomes in 1174 patients. 1998
Role of the platelet FcRIIa polmorphism in idiopathic thrombocytopenia purpura (ITP). 1998
Severe neonatal alloimmune thrombocytopenia due to a novel low-frequency alloantigen, Dy-a. 1998
Storage and processing of multimerin expressed in AtT 20 cells: Similarities and differences to platelet and endothelial cell-derived multimerin 1998
Successful treatment of Clostridium associated hemolytic syndrome by plasmapheresis. 1998
The effect of heparin and low molecular weight heparin on osteoblastogenesis in vitro. 1998
The study of PAIgG distribution in patients with immune and nonimmune thrombocytopenia using confocal microscopy. 1998
Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT. 1998
Vitronectin mediates the high affinity binding of plasminogen activator inhibitor-1 to fibrin. 1998
A prospective study of antigen capture assays for the investigation of idiopathic thrombocytopenic purpura (ITP). 1997
Adenoviral-based gene transfer of two forms of stem cell factor to human bone marrow stromal cells. 1997
Aspirin resistance using flow cytometry. 1997
BCL-2 and Bax regulate apoptosis from different subcellular compartments. 1997
Both thrombin exosites are required to form a ternary thrombin-heparin-fibrin complex that attenuates thrombin inhibition. 1997
Characterization of recombinant multimerin. 1997
Development of conditions for the ex vivo culture of a novel CD34 negative population of primitive human hematopoietic repopulating cells. 1997
Differential expression and synthesis of GRP78 and HSP70 by homocysteine. 1997
Electronic and printed syllabi describing 1) human hemoglobin variants and 2) determinants of thalassemia and HPFH. 1997
Exposure in vivo of rabbit platelets to thrombospheres augments the ADP-induced decrease in platelet phosphatidylinositol 4,5-bisphosphate (PIP2) ex vivo. 1997
Glycophorin-A ligands cause hemolysis in-vitro. A novel hemolytic mechanism of potential clinical relevance. 1997
Heparin binds to tissue factor: An explanation for heparin's limited effect on the prothrombin time. 1997
Homocysteine alters mitochondrial gene expression, function and structure. 1997
Identification of a novel CD34 negative population of primitive human hematopoietic cells capable of repopulating NOS/SCID mice. 1997
Incremental cost effectiveness of maintaining dose intensity with G-CSF as primary therapy of intermediate grade non-Hodgkin's lymphoma. 1997
Intramarrow administration of an adenoviral vector expressing canine GM-CSF to alleviate neutropenia in dogs treated with chemotherapy. 1997
Isolation and characterization of cultured human dendritic cells: A potential target for adenoviral-based gene transfer of tumour peptides. 1997
Management of the initial phase of warfarin treatment: Retrospective analysis of post-operative heart valve replacement patients compared with nonsurgical patients. 1997
Measurement of endogenous and exogenous alpha granular platelet proteins in patients with immune and nonimmune thrombocytopenia. 1997
Mutations in the glycosaminoglycan-binding domain of heparin cofactor II result in variants with increased thrombin inhibitory activity. 1997
Normal development of an infant with homozygous a thalassemia. 1997
Persistence of anti-glycoprotein IIb/IIIa antibodies in patients in complete remission from idiopathic thrombocytopenic purpura (ITP). 1997
Plasma cell vaccine production: Negative selection, adenoviral infection and in vivo expression of vector derived interleukin 2 (IL-2). 1997
Sequestration of the Gov alloantigens into low density high molecular weight membrane fractions isolated from human platelets. 1997
Studies of multimerin and platelet alpha-granular proteins in platelet low type 1 and type 3 von Willebrand disease. 1997
Sulfated low molecular weight heparin is a potent inhibitor of intrinsic tenase and prothrombinase. 1997
The fibrin-specificities of tissue-type plasminogen activator and, to a lesser extent, the TNK variant are compromised by kringle-dependent interactions with (DD)E. 1997
The value of bilateral venous compression ultrasonography in patients with suspected pulmonary embolism (PE). 1997
Unusually severe presentation of sickle cell disease in patients with triplicated and quadruplicated alpha gene loci 1997
Using engineered allografts to improve transplant outcome in multiple myeloma (MM). 1997
Vasoflux, a novel anticoagulant that is more effective than heparin and safer than hirudin in rabbits. 1997
alpha-granular protein degradation in the Quebec platelet disorder is associated with abnormal secretable platelet serine protease activity. 1997
A novel and de novo spontaneous point mutation (GLU270STOP) of the antithrombin (AT) gene results in a type I deficiency and congenital thrombophilia. 1996
ABH antigens are expressed on the GPI-anchored protein, CDw109, on human platelets. 1996
Alternative splicing leads to the frequent co-expression of p190BCR-ABL and p210BCR-ABL transcripts in the chronic phase of chronic myelogenous leukemia. 1996
Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types. 1996
Broad spectrum of beta-thalassemia mutations in Alexandria, Egypt. 1996
Causes of death in Canadians with Hemophilia 1980-1995. 1996
Clot-bound thrombin activates platelets as potent as fluid-phase thrombin. 1996
Comparative study of laboratory diagnosis of alpha-thalassemia. 1996
Comparison of initial clinical characteristics between Asian and Italian multiple myeloma (MM) patients entering the International Oncology Study Group (IOSG) MM1 and the Italian MM study group protocols. 1996
Evaluation of a screening test for the Quebec qualitative platelet 1996
Expressed sequence tag (EST) analysis of murine yolk sac derived embryonic erythroid cells. 1996
FLT3 ligand downregulates B-lymphopoiesis in NOD/SCID mice engrafted with CD34(++)/38(-) hematopoietic stem cells 1996
Fibrinogen inhibits platelet activation by alpha-thrombin and trap. 1996
First report of long-term elimination of red cell transfusions in thalassemia major through augmentation of fetal hemoglobin with sodium phenylbutyrate (SPB) and hydroxyurea (HU). 1996
Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: Response rates and toxicity. 1996
Investigations of endothelial multimerin: Sorting to distinct secretory granules and extracellular matrix structures. 1996
Low-dose oral vitamin K for the reversal of warfarin associated coagulopathy 1996
Maternal alloimmunization to the Gov(a)/Gov(b) antigens on human platelets. 1996
Measurement of platelet procoagulant activity in heparin induced thrombocytopenia. 1996
Monitoring interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation: A marker of acute graft-versus-host disease 1996
Novel mutation of the alpha 2-globin gene initiation codon (ATG->A-G) in a Vietnamese girl with Hb H disease. 1996
Persistent survival of platelet factor Va activity in plasma. 1996
Population screening for the thalassemias and hemoglobinopathies in Hong Kong. 1996
The degradation of the alpha-granule membrane and its soluble contents in the Quebec, qualitative platelet disorder is not secondary to a defect in targeting proteins to alpha-granules. 1996
The human HPA-1 alloantigen system is absent on murine platelets. 1996
The loss of factor VIII activity during storage in PVC containers is due to protein adsorption and not proteolytic degradation. 1996
The value of the SimpliRed(R) D-dimer in a prospective management study of patients with suspected pulmonary embolism (PE). 1996
Use of a clinical model in a prospective management study of patients with suspected pulmonary embolism (PE). 1996
Activated protein C resistance is not associated with postoperative deep vein thrombosis in patients undergoing hip or knee surgery. 1995
Acute transfusion reactions in pediatric patients. 1995
Administration of no-affinity heparin (NAH) in vivo alters the tissue localisation and metabolism of unfractionated heparin (UFH). 1995
Alloimmune thrombocytopenia in two recipients of kidney transplants from same donor. 1995
Altered blood lipid metabolism in children with acute lymphoblastic leukemia (ALL). 1995
Altered recovery but not clearance contributes to the variation in anticoagulant response to heparin in vivo. 1995
Bax is induced following retinoic acid treatment but cell survival depends on Bcl-2 expression 1995
Calpain activity in bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). 1995
Catalytically equivalent doses of heparin and dermatan sulphate inhibit platelet-dependent prothrombinase formation to the same extent in plasma. 1995
Changes in quality of life during the first year after bone marrow transplantation: A prospective study. 1995
Characterization of the interactions of lys-plasminogen and tissue and vampire bat plasminogen activators with fibrin and (DD)E. 1995
Critical appraisal of interferon therapy for chronic myeloid leukemia. 1995
De Novo deletion of the entire zeta-alpha globin gene cluster in a girl with HB H disease 1995
Development of an elastase-resistant antithrombin through mutagenesis at P4. 1995
Epitope specificity of the antibodies in sera of patients with heparin induced thrombocytopenia. 1995
Etretinate: A novel agent for the treatment of refractory sclerodermatous chronic graft versus host disease. 1995
Evidence for in vivo thrombin generation following the transfusion of blood from a post-operative drainage device. 1995
FC(gamma)IIA receptor genotype heterogeneity and platelet activation by heparin-induced thrombocytopenia IgG (HIT-IgG): A possible explanation for the predominance of the ''low responder'' (his(131)) Fc(gamma)IIA receptor genotype in HIT patients. 1995
Feasibility of using recombinant factor VIIa in continuous infusion. 1995
Formation of heparin-induced thrombocytopenia IgG (HIT-IgG) without thrombocytopenia: Analysis of a clinical trial. 1995
Home therapy for minor surgery and major bleeding using continuous infusion of monoclonal antibody purified factor VIII concentrate. 1995
Identification of genes during murine embryonic erythropoiesis 1995
Intra-marrow administration of adenoviral vectors for localized cytokine delivery. 1995
Isolation and characterization of cysteine protease in thrombotic thrombocytopenic purpura. 1995
Lightning strikes twice: Glanzmann's thrombasthenia in two half-sisters. 1995
Low risk of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disease (PTLD) in patients receiving elutriated allogeneic marrow transplants may reflect depletion of EBV infected lymphocytes from the graft. 1995
Maintenance of tight-binding thrombin inhibition of hirudin fused to albumin via its carboxy-, but not amino-terminus. 1995
Multimerin deficiency in a second Quebec family. 1995
South-east Asian ovalocytic (SAO) erythrocytes have a cold sensitive cation leak: Implications for studies of in vitro invasion of stored SAO red cells by Plasmodium falciparum malarial parasites. 1995
Splenectomy reduces the frequency of relapse in patients with chronic relapsing TTP. 1995
The effect of targeting Bcl-2 to different intracellular compartments 1995
The morphology of acute leukemia with 15;17 translocation: Further variants of APL, implications in regard to early ATRA therapy. 1995
The role of Bcl-2 expression in mediating cisplatinum resistance. 1995
Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 (CK18) on the surface of hepatocytes. 1995
Thrombin-mediated platelet activation is due to the cleavage of the cloned thrombin receptor and independent of platelet glycoprotein Ib. 1995
2-CHLORODEOXYADENOSINE (2CDA) FOR DISORDERS OF MONO-HISTIOCYTIC (MO/HI) LINEAGE 1994
A PROSPECTIVE-STUDY OF HEPARIN-INDUCED THROMBOCYTOPENIA - UNFRACTIONATED HEPARIN COMPARED WITH LOW-MOLECULAR-WEIGHT HEPARIN 1994
ABNORMALITIES IN FIBRINOLYSIS PREDICT FOR RECURRENT DEEP-VEIN THROMBOSIS 1994
CYCLOHEXIMIDE AND ACTINOMYCIN INHIBIT CYTOKINE ACCUMULATION DURING PLATELET CONCENTRATE STORAGE 1994
DAY-6 BONE-MARROW (D6BM) PREDICTS FOR COMPLETE REMISSION (CR) IN ADULTS WITH ACUTE MYELOID-LEUKEMIA (AML) 1994
DETECTION OF PLATELET-ASSOCIATED AUTOANTIBODIES TO THE GP-IIB/IIIA COMPLEX BY DIRECT RADIOIMMUNO-PRECIPITATION - A SPECIFIC TEST FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA 1994
EFFECTIVE CYTOKINE GENE-TRANSFER IN HUMAN LONG-TERM BONE-MARROW CULTURED-CELLS USING ADENOVIRAL VECTORS 1994
EVALUATION OF THE FC RECEPTOR IIA GENOTYPE FREQUENCIES AMONG PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA 1994
EXPRESSION OF CANINE FACTOR-IX BY TRANSDUCED LONG-TERM CULTURE ADHERENT CELLS, AND THEIR ENGRAFTMENT IN THE CANINE BONE-MARROW COMPARTMENT FOLLOWING AUTOLOGOUS TRANSPLANTATION 1994
FACTOR-V IS COMPLEXED WITH MULTIMERIN IN RESTING PLATELET LYSATES AND COLOCALIZES WITH MULTIMERIN WITHIN PLATELET ALPHA-GRANULES 1994
GENERATION OF PLATELET-DERIVED MICROPARTICLES AND PROCOAGULANT ACTIVITY BY IGG PLATELET AGONISTS - COMPARISON WITH STANDARD PLATELET AGONISTS 1994
HEPARIN-INDUCED THROMBOCYTOPENIA - PREDOMINANCE OF VENOUS THROMBOTIC COMPLICATIONS, AND A HIGH-RISK FOR SUBSEQUENT THROMBOSIS IN PATIENTS WHO ARE INITIALLY RECOGNIZED WITH ISOLATED THROMBOCYTOPENIA 1994
HETEROGENEITY OF THE MEMBRANE ANCHOR FOR GP175 EXPRESSING THE GOV ALLOANTIGEN SYSTEM 1994
IDENTIFICATION OF AN AUTOSOMAL-DOMINANT BLEEDING DISORDER THAT IS ASSOCIATED WITH A DEFICIENCY OF PLATELET MULTIMERIN AND A DEFECT IN PLATELET FACTOR-V 1994
LONG-TERM TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THALASSEMIA - REDUCTION IN REQUIREMENT FOR TRANSFUSION AND CHELATION-THERAPY 1994
PLATELETS ARE THE PRIMARY SOURCE OF FACTOR VA FOR PROTHROMBINASE FORMATION IN PLATELET-RICH PLASMA 1994
SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) VERSUS WARFARIN SODIUM (WS) FOR PROPHYLAXIS OF DEEP-VEIN THROMBOSIS (DVT) AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT (THR/TKR) - AN ECONOMIC-PERSPECTIVE 1994
TELOMERE LENGTH AND TELOMERASE ACTIVITY IN HEMATOLOGIC MALIGNANCIES 1994
THE CDNA SEQUENCE OF HUMAN ENDOTHELIAL-CELL MULTIMERIN - A NOVEL PROTEIN WITH RGDS, COILED-COIL, AND EGF DOMAINS, AND A CARBOXYL-TERMINUS SIMILAR TO THE GLOBULAR DOMAINS OF THE TRIMERIC PROTEINS C1Q AND COLLAGENS TYPE-VIII AND TYPE-X 1994
THE DEVELOPMENT AND EVALUATION OF A NOVEL TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA 1994
THE EFFECT OF GAMMA-IRRADIATION ON INTERLEUKIN-1-BETA (IL-1-BETA) AND INTERLEUKIN-6 (IL-6) ACCUMULATION DURING PLATELET CONCENTRATE STORAGE 1994
THE ROLE OF PLATELET ALLOANTIGEN GENOTYPING AND VNTR ANALYSIS USING DNA-DERIVED FROM AMNIOTIC-FLUID IN THE MANAGEMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIA 1994
USE OF VARIOUS INDEXES IN POPULATION-BASED SCREENING FOR THALASSEMIA - UTILITY OF THE MEAN CORPUSCULAR VOLUME 1994
VITAMIN-B12 DEFICIENCY IN A BREAST-FED INFANT SECONDARY TO MATERNAL LATENT PERNICIOUS-ANEMIA 1994
A CRITICAL ANALYSIS OF THE ACCURACY OF ULTRASOUND (US) FOR THE DIAGNOSIS OF DEEP-VEIN THROMBOSIS (DVT) IN ASYMPTOMATIC POSTOPERATIVE-PATIENTS 1993
ADJUSTED-DOSE CONTINUOUS-INFUSION OF FACTOR CONCENTRATE 1993
AN ACUTE, SPECIFIC EFFECT OF DEXAMETHASONE ON OSTEOBLASTIC ACTIVITY IN CHILDREN WITH LYMPHOBLASTIC-LEUKEMIA (ALL) 1993
APPARENT ENGRAFTMENT OF TRANSDUCED LONG-TERM CULTURE ADHERENT CELLS INTO THE CANINE BONE-MARROW COMPARTMENT, FOLLOWING INTRAVENOUS OR DIRECT INTRA-MARROW INFUSION 1993
BIOCHEMICAL-CHARACTERIZATION OF THE GOV ALLOANTIGEN ON HUMAN PLATELETS AND CELL-LINES 1993
CHARACTERIZATION OF MULTIMERIN EXPRESSION ON PLATELETS ACTIVATED IN-VITRO AND IN-VIVO 1993
CIRCULATING PLATELET-DERIVED MICROPARTICLES IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA 1993
DISORDERED AUTONOMIC MODULATION OF THE HEART-RATE IN SURVIVORS OF LYMPHOBLASTIC-LEUKEMIA (ALL) IN CHILDHOOD 1993
DOES VITAMIN-C CAUSE HEMOLYSIS IN PREMATURE NEWBORNS - RESULTS OF A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL 1993
EFFICACY OF ANTI-D TO IMPROVE PLATELET TRANSFUSION RESPONSE - A RANDOMIZED TRIAL 1993
EVIDENCE FOR PROMISCUOUS MEMBRANE ASSEMBLY OF BCL-2 1993
EXPLOSIVE GRAFT-VERSUS-HOST DISEASE 1993
IDENTIFICATION OF A NOVEL TERMINATION CODON MUTATION (TAA-]TAT) IN THE ALPHA-2 GLOBIN GENE OF A GIRL WITH HEMOGLOBIN-H DISEASE 1993
IGG FROM PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) BINDS TO A PF4/HEPARIN COMPLEX AND NOT TO HEPARIN ALONE 1993
PRENATAL-DIAGNOSIS OF HEMOGLOBINOPATHIES IN ONTARIO - A REVIEW OF 100 CASES 1993
SPECTRUM OF BETA-THALASSEMIA MUTATIONS IN ONTARIO - 3 NOVEL FRAMESHIFT MUTATIONS IDENTIFIED BY NUCLEOTIDE SEQUENCING 1993
ADULT HEMOGLOBIN IN YOLK-SAC DERIVED PRIMITIVE NUCLEATED ERYTHROCYTES IN NORMAL AND MUTANT TS-+ FETAL MICE 1977
DEFECT IN DIFFERENTIATION FROM BFU-E TO CFU-E DURING EARLY FETAL HEPATIC ERYTHROPOIESIS IN STEEL MUTANT MICE 1977
EFFECT OF ASPIRIN ON DIPYRIDAMOLE PLASMA-LEVEL, DISTRIBUTION AND CLEARANCE 1977
LOW-DOSE HEPARIN PROPHYLAXIS - EFFICACY WITH OMISSION PREOPERATIVE DOSE 1977
OBSERVER VARIATION IN INTERPRETATION OF VENOGRAMS 1977
SPUR CELLS - EFFECT OF CHOLESTEROL-LOADING OF RED BLOOD-CELLS (RBC) ON MEMBRANE-BOUND PROTEIN-KINASE (PKASE) 1977
UNEQUAL ALPHA-GLOBIN AND BETA-GLOBIN MESSENGER-RNA IN RETICULOCYTES OF NORMAL AND MUTANT F-F FETAL MICE 1977
VALUE OF COMBINING IMPEDANCE PLETHYSMOGRAPHY (IPG) WITH 125I-FIBRINOGEN LEG SCANNING (LEG SCANNING) AS A SCREENING-PROCEDURE IN ORTHOPEDIC AND NON-ORTHOPEDIC PATIENTS 1977
DEVELOPMENT OF ANTI-HEPARIN ACTIVITY IN STORED VACUTAINER TUBES 1976
T CELL DERIVED STIMULANT OF HUMAN STEM-CELL 1975
Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia.. 144:2018-2032. 2024
A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. 144:1985. 2024
A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). 144:2000.2-2000.2. 2024
A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). 144:989-989. 2024
An Evaluation of Andexanet Alfa v. Standard of Care for Reversal of Doac-Induced Intracranial Hemorrhage - a Systematic Review and Meta-Analysis. 144:5089. 2024
COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy. 144:286. 2024
Changing the Serum Ferritin Lower Limit of Normal to a Clinical Decision Limit: An Acceptability Survey. 144:7561-7561. 2024
Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination. 144:1243-1243. 2024
Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study. 144:547-547. 2024
Development of a National Needs Driven Intrinsic Roles Curriculum for Canadian Hematology Residency Training Programs. 144:3821-3821. 2024
Development of an Electronic Learning Module for CAR-T Education in Canadian Hematology Residents. 144:3822-3822. 2024
Diagnostic Accuracy of Erythropoietin and Jakpot in Predicting JAK2-Postiive Erythrocytosis: A Retrospective Cohort Study. 144:5017-5017. 2024
Examining the Clinical Relevance of the AML Plasma Metabolome. 144:2937-2937. 2024
Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research. 144:1927.1. 2024
Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). 144:1994. 2024
From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation. 144:3634-3634. 2024
Genetic or Epigenetic CR1 Deficiency Defines Catastrophic Antiphospholipid Syndrome (CAPS) and Response to Complement Inhibition. 144:138. 2024
Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis. 144:4721. 2024
Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses. 144:6291-6291. 2024
Inflammation in Myeloproliferative Philadelphia Chromosome Negative Neoplasms - Relationship with Biomarkers of Disease Activity. 144:6631-6631. 2024
Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee. 144:5166-5166. 2024
Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study. 144:3753-3753. 2024
Longitudinal Laboratory and Clinical Outcomes in Vaccine-Induced Immune Thrombotic Thrombocytopenia after 3 Years. 144:5523-5523. 2024
Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody. 144:4757.1. 2024
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?. 144:7418. 2024
Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis. 144:704. 2024
Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study. 144:6281. 2024
Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients - a Multicenter Canadian Study. 144:4878-4878. 2024
Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate. 144:795. 2024
Quality of Life, Physical and Mental Health of Patients with Vaccine Induced Immune Thrombotic Thrombocytopenia after Extended Followup. 144:5083-5083. 2024
Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM). 144:3355-3355. 2024
Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium. 144:3368-3368. 2024
Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada. 144:5170.3-5170.3. 2024
Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index. 144:2565-2565. 2024
Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy. 144:3749-3749. 2024
The Role of JAK2 Allele Burden on Muscle Strength and Physical Functioning in Patients with Myeloproliferative Neoplasm: A Systematic Review and Prospective Cohort Analysis. 144:6672-6672. 2024
The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid. 144:2764. 2024
Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). 144:703. 2024
ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma. 144:6916-6916. 2024
Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis. 144:6986. 2024
Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis. 144:4007-4007. 2024
4D intravital imaging identifies platelets as the predominant cellular procoagulant surface in a mouse hemostasis model. 144:1116-1126. 2024
CHC and surgery: when is stopping safe?. 143:9-10. 2024
Deep learning for platelet transfusion. 142:2231-2232. 2023
Ureaplasma-Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant. 142:6988-6988. 2023
Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant. 142:2211-2211. 2023
Chronic TNF in the Aging Microenvironment Exacerbates TET2-loss-of-Function Myeloid Expansion. 142:938-938. 2023
Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study. 142:541-541. 2023
Decoding the Epigenetic Drivers of Menin-MLL Inhibitor Resistance in KMT2A-Rearranged Acute Myeloid Leukemia. 142:587. 2023
Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada. 142:1954-1954. 2023
Effects of Prolonged Tourniquet Application on Coagulation and Fibrinolysis in Rats. 142:5411-5411. 2023
Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial. 142:4751-4751. 2023
Efficacy of Maintenance Therapies By Prognostic Subgroups in Post-Transplant Newly Diagnosed Multiple Myeloma Patients: A Systematic Review and Network Meta-Analysis. 142:3348-3348. 2023
Efficacy of Vitamin C with Iron Supplementation in Iron Deficiency Anemia Patients: A Systematic Review and Meta-Analysis. 142:1091-1091. 2023
Evaluating Hemoglobin Thresholds on the Basis of Sex: Preliminary Insights from a Systematic Review. 142:7200-7200. 2023
Evaluation of Bleeding Self-Assessments By Patients with Immune Thrombocytopenia (ITP): An Agreement Study. 142:3958-3958. 2023
Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review. 142:3363-3363. 2023
Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study. 142:785-785. 2023
Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM). 142:3037-3037. 2023
LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses. 142:6793-6793. 2023
LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism. 142:4156-4156. 2023
Leukostasis Twist in Mantle Cell Lymphoma: Systematic Review and Case Report. 142:6132-6132. 2023
Monoclonal Immunoglobulin Deposition Disease - a Review of Current and Emerging Data. 142:6757-6757. 2023
Obstetrical Use of Intravenous Immunoglobulin at a Tertiary Care Canadian Center: A 14-Year Retrospective Study. 142:5561-5561. 2023
Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A. 142:506-506. 2023
Platelet Count Response to Obstetrical Use of IVIG for Maternal Thrombocytopenia: A 14-Year Retrospective Study. 142:2583-2583. 2023
Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial. 142:4756-4756. 2023
Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients. 142:542-542. 2023
Risk of Anemia and Vitamin B12 Deficiency in Patients with Type 2 Diabetes Mellitus on Metformin Therapy: A Systematic Review and Meta-Analysis. 142:5201-5201. 2023
Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial. 142:3042-3042. 2023
Safety and Efficacy of Direct Oral Anticoagulants in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. 142:5534-5534. 2023
Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. 142:3364-3364. 2023
Surgical Procedures and Hemostatic Outcome in Patients with Hemophilia Receiving Concizumab Prophylaxis during the Phase 3 explorer7 and explorer8 Trials. 142:30-30. 2023
The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0. 142:1212-1212. 2023
Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. 142:3774-3774. 2023
Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review. 142:7239-7239. 2023
Impact of Vincristine-Steroid Pulses in Maintenance for B-Cell Pediatric ALL: A Systematic Review and Meta-Analysis. 141:2944-2954. 2023
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets. 141:2214-2223. 2023
Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. 141:1982-1989. 2023
The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. 141:1147-1158. 2023
A Retrospective Cohort Study of Donor Cell Leukemia. 140:12916-12917. 2022
Defining Ferritin Clinical Decision Limits to Improve Diagnosis and Treatment of Iron Deficiency: A Modified Delphi Study. 140:11082-11084. 2022
Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia. 140:5640-5641. 2022
Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. 140:8036-8037. 2022
Predictors of Disease Progression and Survival in Patients with Myelodysplastic Syndrome Secondary to Inherited Bone Marrow Failure Syndromes. 140:11461-11462. 2022
Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia. 140:5640-5641. 2022
PLAG1 dampens protein synthesis to promote human hematopoietic stem cell self-renewal. 140:992-1008. 2022
ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. 140:274-284. 2022
Heparin or nonheparin anticoagulants for VITT. 139:3358-3359. 2022
A Micro-lyse goes a long way. 139:477-479. 2022
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. 138:2256-2268. 2021
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. 138:2173-2184. 2021
Inhibiting Mitochondrial Complex II Exposes a Novel Metabolic Vulnerability in Acute Myeloid Leukemia. 138. 2021
Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data. 138:565-565. 2021
Comparing Exercise-Induced Musculoskeletal Bleeding in Murine Models of Hemophilia A and B. 138:1031-1031. 2021
Iron Chelation Therapy in Low- to Intermediate- Risk Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis. 138:4661-4661. 2021
Perioperative Anemia Management in Women Undergoing Gynecologic Procedures: A 10 Year Multisite Study. 138:752-752. 2021
Pharmacist Integration into the Hemophilia Treatment Centre: A Canadian Pilot Project to Optimize Treatment and Improve Cost-Savings Using Pharmacokinetic Assessments of Hemophilia Patients. 138:832-832. 2021
Rates and Predictors of Visits to Primary Care Physicians during and after Treatment of Childhood Acute Lymphoblastic Leukemia: A Population-Based Cohort Study. 138:839-839. 2021
The Impact of Artificial Intelligence on Health Equity in Oncology: A Scoping Review. 138:4934-4934. 2021
Thrombotic Events in COVID-19 Patients Undergoing Convalescent Plasma Therapy: A Systematic Review. 138:3221-3221. 2021
Von Willebrand Factor Expression in Endothelium in a Co-Culturing System of Acute Lymphoblastic Leukemia. 138:4206-4206. 2021
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. 138:1269-1277. 2021
A long-half-life, high-affinity P-selectin inhibitor. 138:1096-1097. 2021
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. 138:299-303. 2021
Very long chain fatty acid metabolism is required in acute myeloid leukemia. 137:3518-3532. 2021
Unraveling von Willebrand factor deficiency. 137:3160-3161. 2021
Enhancer-gene rewiring in the pathogenesis of Quebec Platelet Disorder. 136:2679-2690. 2020
Making a bet on RET for hematopoietic stem cell expansion. 136:2484-2486. 2020
Characterizing Frailty in Myeloproliferative Neoplasms: Baseline Results from the Orchid Study. 136:9-10. 2020
Detection of Right Ventricular Dysfunction in Acute Pulmonary Embolism By CT Scan: A Systematic Review and Meta-Analysis. 136:25-26. 2020
Elucidating Barriers to Advance Care Planning in Malignant Hematology Clinics: A Single Centre Experience in Ontario, Canada. 136:17-18. 2020
Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. 136:45-46. 2020
Fiirst-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients. 136:6-6. 2020
Frequency of Venous Thromboembolism in 6513 Patients with COVID-19: A Retrospective Study. 136:21-22. 2020
Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. 136:38-39. 2020
Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry. 136:8-9. 2020
Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study. 136:46-47. 2020
Increased Health Resource Utilization with the Introduction of Matrix for First-Line Treatment of Primary Central Nervous System Lymphoma. 136:40-41. 2020
Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors. 136:31-32. 2020
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. 136:1433-1441. 2020
COVID-19 coagulopathy, thrombosis, and bleeding. 136:381-383. 2020
Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. 135:1788-1810. 2020
HIT: still stringing us along. 135:1193-1194. 2020
Novel antithrombotic strategies for treatment of venous thromboembolism. 135:351-359. 2020
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. 135:239-251. 2020
Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. 134:4-4. 2019
Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. 133:2455-2459. 2019
Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. 133:2255-2262. 2019
How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. 133:2269-2278. 2019
MAA868 locks factor XIa in a zymogen-like state. 133:1393-1394. 2019
Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. 133:978-989. 2019
Treatment of bleeding complications in patients on anticoagulant therapy. 133:425-435. 2019
Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. 132:2684-2686. 2018
Natural, not immune; classical, not alternative. 132:2421-2422. 2018
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. 132:2147-2147. 2018
Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. 132:3182-3182. 2018
Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. 132:4240-4240. 2018
Fluid-Phase Immune Complexes Can Assemble and Activate Platelets in Heparin-Induced Thrombocytopenia. 132:3746-3746. 2018
Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. 132:3160-3160. 2018
T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. 132:5368-5368. 2018
T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies. 132:3267-3267. 2018
Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. 132:3436-3436. 2018
Higher-risk APS: do we dare to DOAC?. 132:1357-1358. 2018
High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. 132:1345-1349. 2018
AMPK-ACC signaling modulates platelet phospholipids and potentiates thrombus formation. 132:1180-1192. 2018
Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. 132:223-231. 2018
Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD. 131:2863-2866. 2018
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. 131:2183-2192. 2018
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. 131:2151-2160. 2018
The Use of Anticoagulation in Patients With Thrombocytopenia. 15. 2018
Splenectomy for immune thrombocytopenia: down but not out. 131:1172-1182. 2018
Statins for high cholesterol … and for low platelets?. 131:1159-1161. 2018
How I treat heavy menstrual bleeding associated with anticoagulants. 130:2603-2609. 2017
Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). 130:752-752. 2017
The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis. 130:627-627. 2017
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. 130:1706-1712. 2017
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. 130:1706-1712. 2017
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. 130:1104-1113. 2017
Soluble P-selectin is the smoke, not the fire. 130:101-102. 2017
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis. 15:1322-1333. 2017
How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. 129:3285-3293. 2017
Platelet polyphosphate: the long and the short of it. 129:1574-1575. 2017
Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. 129:1538-1547. 2017
Emerging anticoagulant strategies. 129:147-154. 2017
Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. 128:2834-2845. 2016
Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. 128:2548-2548. 2016
Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). 128:2430-2430. 2016
B cells, PF4/heparin complexes, and complement. 128:1781-1782. 2016
Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. 128:1329-1335. 2016
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. 128:934-947. 2016
The role of leukocytes in thrombosis. 128:753-762. 2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. 128:732-735. 2016
How I treat patients with a history of heparin-induced thrombocytopenia. 128:348-359. 2016
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. 128:138-140. 2016
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. 127:3082-3091. 2016
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. 127:2791-2803. 2016
End of the road for heparin thromboprophylaxis. 127:1945-1946. 2016
Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. 127:2035-2037. 2016
Less menorrhagia for women with VTE. 127:1378-1379. 2016
Knee replacement and HIT without heparin. 127:961-962. 2016
Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. 127:400-410. 2016
Monovalent Fc receptor blockade by an anti–Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity. 127:132-138. 2016
Enteropathy-Associated T-Cell Lymphoma: A Single Centre Experience. 126:5057-5057. 2015
Thrombotic Thrombocytopenic Purpura (TTP) Management at Foothills Medical Centre: A Retrospective Analysis Between 2005-2010 (Tertiary Centre, Calgary). 126:4654-4654. 2015
Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. 126:2424-2435. 2015
Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII. 126:939-942. 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. 126:733-738. 2015
Characterization of mice harboring a variant of EPCR with impaired ability to bind protein C: novel role of EPCR in hematopoiesis. 126:673-682. 2015
Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. 126:597-603. 2015
Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. 126:486-493. 2015
Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. 125:3816-3817. 2015
Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. 125:2712-2719. 2015
Platelets: connecting clotting and lysis. 125:2459-2459. 2015
Evidence-based focused review of the role of radiation therapy in the treatment of early-stage Hodgkin lymphoma. 125:1708-1716. 2015
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. 125:1526-1531. 2015
Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study. 125:924-929. 2015
Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. 125:195-198. 2015
Update on the use of hydroxyurea therapy in sickle cell disease. 124:3850-3857. 2014
Inhibition of Plasmin Generation in Plasma By Heparin, Low Molecular Weight Heparin and a Covalent Antithrombin-Heparin Complex (ATH). 124:4217-4217. 2014
Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. 124:1719-1719. 2014
Low Level Platelet-Activating Antibodies in Patients Suspected of Having Heparin-Induced Thrombocytopenia but Testing Negative in the ”Gold Standard” Functional Test. 124:2757-2757. 2014
Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS. 124:314-314. 2014
The Effect of Age on the Glycosylation of Human Alpha-2-Macroglobulin. 124:2800-2800. 2014
The Effects of Thrombocytopenia on Clotting Profile in Whole Blood As Determined By Thromboelastography When Anticoagulant Is Present at Therapeutic or Prophylactic Concentration. 124:1550-1550. 2014
Thromboembolic Events, Recurrent Gastrointestinal Bleeding and Mortality after Resuming Anticoagulant Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. 124:2799-2799. 2014
Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. 124:3608-3612. 2014
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. 124:2450-2458. 2014
Factors that predict thrombosis in relatives of patients with venous thromboembolism. 124:2124-2130. 2014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. 124:1968-1975. 2014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.. 124:1968-1975. 2014
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. 124:1020-1028. 2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. 124:729-736. 2014
Role of phenotypic and genetic testing in managing clopidogrel therapy. 124:689-699. 2014
A von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice. 124:445-452. 2014
Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. 124:142-150. 2014
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. 123:3914-3924. 2014
Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. 123:3651-3654. 2014
Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. 123:2485-2493. 2014
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. 123:2102-2107. 2014
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. 123:1956-1957. 2014
How I treat target-specific oral anticoagulant–associated bleeding. 123:1152-1158. 2014
Platelet transfusions for critically ill patients with thrombocytopenia. 123:1146-1151. 2014
Fetal hemoglobin in sickle cell anemia: a glass half full?. 123:481-485. 2014
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. 123:1794-1801. 2014
Superficial venous thrombosis: recognizing the risk. 122:4159-4160. 2013
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. 122:3879-3883. 2013
Clinical and biological implications of driver mutations in myelodysplastic syndromes. 122:3616-3627. 2013
HbC disorders. 122:3698-3698. 2013
A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. 122:709-709. 2013
Covalent Stabilization Of Coagulation Factor Xa Enhances Its Fibrinolytic Function In Vitro and In Vivo: A Novel Cofactor-Based Thrombolytic Agent. 122:204-204. 2013
Early Mortality In Hyperleukocytosis In Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. 122:2647-2647. 2013
Feasibility Study Of a Randomized Control Trial To Evaluate An Internet-Based Self-Management Program For Adolescents With Hemophilia. 122:2921-2921. 2013
Reversal Of Dabigatran By Recombinant Factor VIIa Is Dependent On The Amount Of Tissue-Factor. 122:1149-1149. 2013
Second Bacteremia During Antibiotic Treatment In Children With Acute Myeloid Leukemia: A Report From The Canadian Infections In AML Research Group. 122:1415-1415. 2013
Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder. 122:2328-2328. 2013
The Architecture Of Fibrin Clots Formed From Plasma With Low Platelet Levels Are Less Altered In The Presence Of Factor-Specific Anticoagulants Compared With Unfractionated Heparin. 122:578-578. 2013
The Efficacy and Safety Of Therapeutic Aheresis In Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. 122:1119-1119. 2013
The Use Of Platelet Transfusions In The Intensive Care Unit and Impact On Platelet Count: A 30,000 Patient Registry Study. 122:1154-1154. 2013
Tranexamic Acid is a Weak Provoking Factor For Thromboembolic Events: A Systematic Review Of The Literature. 122:3629-3629. 2013
Abnormal megakaryocyte development and platelet function in Nbeal2−/− mice. 122:3349-3358. 2013
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. 122:1946-1953. 2013
RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity. 122:1545-1555. 2013
Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cells. 122:1162-1173. 2013
A platelet cover-up. 122:307-309. 2013
The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. 122:376-385. 2013
β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. 121:3889-3899. 2013
EBV DNA: a Hodgkin lymphoma biomarker?. 121:3541-3542. 2013
Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. 121:2821-2827. 2013
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. 121:2432-2439. 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. 121:1517-1523. 2013
Gli3-mediated hedgehog inhibition in human pluripotent stem cells initiates and augments developmental programming of adult hematopoiesis. 121:1543-1552. 2013
Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. 122:817-824. 2013
Blood smear: fulminant pneumococcal bacteremia. 120:4459-4459. 2012
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. 120:4488-4495. 2012
Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. 120:1186-1186. 2012
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. 120:548-548. 2012
Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. 120:4160-4167. 2012
How I treat anticoagulated patients undergoing an elective procedure or surgery. 120:2954-2962. 2012
Clotting factor concentrate switching and inhibitor development in hemophilia A. 120:720-727. 2012
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. 119:3016-3023. 2012
Asymmetric segregation and self-renewal of hematopoietic stem and progenitor cells with endocytic Ap2a2. 119:2510-2522. 2012
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. 119:2172-2174. 2012
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. 119:1356-1362. 2012
HIT: treatment easier, prevention harder. 119:1099-1100. 2012
Safety of anticoagulants in children with arterial ischemic stroke. 119:949-956. 2012
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. 118:6667-6674. 2011
Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 118:6269-6273. 2011
4Ts HIT Scoring in the Medical-Surgical ICU. 118:4669-4669. 2011
A Functional In Vivo RNAi screen Involving Jumonji C Domain Containing Candidates Unravels Kdm5b As a Negative Modulator of Hematopoietic Stem Cell Self-Renewal. 118:385. 2011
A Retrospective Review of the Management of Patients with Porphyria Cutanea Tarda At a Tertiary Care Centre. 118:5290-5290. 2011
Bone Marrow Specimens From Patients with Immune Thrombocytopenia (ITP) Demonstrate Increased Megakaryocyte-Bound IgG and Increased T-Helper Cells. 118:2233-2233. 2011
Co-Administration Therapy Modulates Immunity to FVIII In Hemophilia A Mice. 118:1219-1219. 2011
Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. 118:2091-2091. 2011
Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. 118:1236-1236. 2011
Exploring the Impact of Clinical Anticoagulants on Venous Thrombosis Stability Using a Novel Intravital Murine Model. 118:1246-1246. 2011
Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study. 118:2299-2299. 2011
Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. 118:590-590. 2011
Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,. 118:3332-3332. 2011
Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,. 118:3304-3304. 2011
Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. 118:26. 2011
Inhibition of Red Blood Cell-Prothrombinase by Heparin and a Covalent Antithrombin-Heparin Complex. 118:1179-1179. 2011
Laboratory HIT Testing in Critically Ill Patients. 118:198-198. 2011
Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). 118:2068-2068. 2011
Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. 118:544. 2011
Relationship Between Subtherapeutic Warfarin Anticoagulation and the Development of Post Thrombotic Syndrome After a First Unprovoked Deep Vein Thrombosis: Results From the REVERSE Cohort Study. 118:712-712. 2011
Rofecoxib Does Not Appear to Increase the Risk of Venous Thromboembolism: A Systematic Review of the Literature,. 118:3334-3334. 2011
Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. 118:508-508. 2011
The Inappropriate Use of the SimpliRed D-Dimer Assay in the Diagnosis of Venous Thromboembolism,. 118:4207-4207. 2011
Usability Testing of An Online Transition Program for Adolescents with Hemophilia. 118:4777-4777. 2011
Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. 118:4036-4040. 2011
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. 118:3350-3358. 2011
Fetal hemoglobin in sickle cell anemia. 118:19-27. 2011
Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. 117:7112-7120. 2011
Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. 117:5044-5049. 2011
A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. 117:4935-4945. 2011
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. 117:4190-4207. 2011
Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. 117:4134-4141. 2011
Salivary microvesicles clot blood. 117:2989-2989. 2011
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. 117:2668-2680. 2011
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. 117:2451-2459. 2011
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. 117:2089-2092. 2011
CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. 117:1146-1155. 2011
RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity. 117:e27-e38. 2011
The “age” of understanding VKA dose. 116:5789-5790. 2010
Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. 116:5716-5723. 2010
A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. 116:710. 2010
A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial. 116:39-39. 2010
A Randomized, Controlled Trial of Varying D-Dimer Cutpoints According to Clinical Pretest Probability Compared with a Uniform D-Dimer Cutpoint for Diagnosis of Deep Vein Thrombosis. 116:5116-5116. 2010
Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. 116:238. 2010
Combinations of Epigenetic Modifying Agents Accentuate Retinoid-Mediated Gene Expression Over Single Agent Therapies In Acute Myelogenous Leukemia Cells. 116:2497-2497. 2010
Comparison of Incidence and Investigation of In-Hospital Pulmonary Embolism In Patients Receiving Dalteparin Prophylaxis Following Elective Knee Replacement at Two Hospitals. 116:4388-4388. 2010
Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells. 116:3278-3278. 2010
Gpx3 Determines Competitiveness of Normal and Leukemic Stem Cells.. 116:1587. 2010
Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies]. 116:3169-3169. 2010
Investigating the Experiences and Educational Needs of Adolescents with Hemophilia Prior to Transition of Care: A Website Development Project.. 116:1526-1526. 2010
Prothrombin Complex Concentrate (Octaplex®) In Patients Requiring Immediate Reversal of Vitamin K Antagonist Anticoagulation.. 116:1115-1115. 2010
Rates of Non-Transfusional Iron Accumulation (NTIA) In Hemoglobin E Thalassemia. 116:5147-5147. 2010
SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature.. 116:1113-1113. 2010
Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.. 116:3800. 2010
The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness: A Systematic Review. 116:4664-4664. 2010
The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia.. 116:3691-3691. 2010
Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study. 116:392-392. 2010
Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. 116:4209-4209. 2010
Variability In Hb A2 levels among Individuals with Beta-Thalassemia Trait: Is Iron Deficiency Associated with Abnormally Low Hb A2?. 116:4281. 2010
Systematic review and meta-analysis methodology. 116:3140-3146. 2010
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. 116:2237-2240. 2010
DITP causation: 3 methods better than 1?. 116:2002-2003. 2010
Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration. 116:2160-2163. 2010
The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. 116:1433-1442. 2010
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. 115:4991-4998. 2010
Bone marrow as a site for pancreatic islet transplantation. 115:3643-3644. 2010
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5′ olfactory receptor gene cluster. 115:1815-1822. 2010
HIT: more than just heparin. 115:1664-1665. 2010
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. 115:1351-1353. 2010
Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. 115:1264-1266. 2010
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. 115:29-31. 2010
The new oral anticoagulants. 115:15-20. 2010
Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B. 114:4907-4908. 2009
A Cohort Study of Warfarin Administered to Achieve An INR of 2.0 to 3.0 for the Prevention of Recurrent Venous Thrombosis in Patients with An Antiphospholipid Antibody.. 114:3123-3123. 2009
A Multifaceted Strategy to Reduce Inappropriate Use of Fresh Frozen Plasma Transfusions in the Intensive Care Unit.. 114:1412-1412. 2009
Adjudicating Bleeding Outcomes in a Large Thromboprophylaxis Trial in Critical Illness.. 114:2471-2471. 2009
An RNA Interference Screen Identifies the Cell Fate Determinants Msi2 and Prox1 as Novel Regulators of Hematopoietic Stem Cell Self-Renewal.. 114:394. 2009
Cerebral Venous Thrombosis During Pregnancy in the Setting of Type I Antithrombin Deficiency: Case Report and Literature Review.. 114:4447-4447. 2009
Covalent Antithrombin-Heparin Complex Catalysis of Activated Protein C Inhibition by Protein C Inhibitor.. 114:3167-3167. 2009
Critical Values in the Coagulation Laboratory: Results of a Survey of the North American Specialized Coagulation Laboratory Association.. 114:1415-1415. 2009
Diagnostic Cytogenetic Analysis in Pediatric Acute Myeloid Leukemia (AML): Evaluation of Methodological Issues with a Special Focus On Missing Data.. 114:4688-4688. 2009
Diagnostic Utility of Platelet Secretion Testing by ATP Release Assays: Results From a Prospective Study of Individuals Referred for Bleeding Disorder Assessments.. 114:1314-1314. 2009
Distribution and Clinical Signs of Venous, Arterial and Intracardiac Clots After Pediatric Cardiac Surgery.. 114:3992-3992. 2009
Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.. 114:1390-1390. 2009
Extended Follow-up of the Multi-Center Multi-National Prospective Cohort Study That Derived the “Men Continue and HERDOO2” Clinical Decision Rule Which Identifies Low Risk Patients Who May Be Able to Discontinue Oral Anticoagulants (Oac) 5-7 Months After Treatment for Unprovoked Venous Thromboembolism (VTE).. 114:451-451. 2009
Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease.. 114:3576-3576. 2009
Histone Demethylases as Modulators of Hematopoietic Cell Fate.. 114:393. 2009
Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. 114:3993-3993. 2009
Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically Ill Patients.. 114:3995-3995. 2009
Investigation Into Mechanisms of Prothrombinase Complex Inhibition by a Covalent Antithrombin-Heparin Complex.. 114:2136-2136. 2009
Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients.. 114:389-389. 2009
Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin in Patients with Immune Thrombocytopenic Purpura.. 114:2418-2418. 2009
Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors.. 114:2978-2978. 2009
Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.. 114:3494. 2009
Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. 114:3154. 2009
Spectral Analysis of Platelet Oscillations in Cyclic Thrombocytopenia.. 114:4459-4459. 2009
The Kids-DOTT Trial: Novel Aspects of the ‘Parallel Cohort RCT‘ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. 114:4169-4169. 2009
The Quality and Accuracy of Hemophilia Information on the Internet.. 114:244-244. 2009
Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease.. 114:3584-3584. 2009
BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cβ. 114:4186-4196. 2009
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. 114:2632-2638. 2009
Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. 114:952-956. 2009
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. 114:779-784. 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. 114:257-260. 2009
A case of apples and pears?. 113:6259-6260. 2009
JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. 113:5617-5623. 2009
Studies of the immune response in heparin-induced thrombocytopenia. 113:4963-4969. 2009
The temporal profile of the anti-PF4/heparin immune response. 113:4970-4976. 2009
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. 113:3673-3678. 2009
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. 113:2386-2393. 2009
P-selectin ready for prime time?. 113:1860-1860. 2009
Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. 113:1809-1817. 2009
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. 113:1564-1573. 2009
Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. 113:1535-1542. 2009
Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. 113:1543-1546. 2009
NKT-cell help to B lymphocytes can occur independently of cognate interaction. 113:370-376. 2009
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. 112:4639-4645. 2008
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. 112:4432-4436. 2008
Age-Related Differences in the Glycosylation of Anticoagulant Protein C.. 112:2031-2031. 2008
Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients. 112:170-170. 2008
An RNA Interference Screen Reveals Fate Determinants Implicated in Asymmetric Cell Division as Potential Regulators of Hematopoietic Stem Cell Self-Renewal. 112:2462. 2008
Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma. 112:4332-4332. 2008
Autoantibodies in Patients with ITP Do Not Bind to Patient-Specific Epitopes on Platelet Glycoproteins.. 112:3427-3427. 2008
Circulating Blasts Are Associated with High Levels of vWF and Thrombin Activation in Children with Newly Diagnosed ALL.. 112:1824-1824. 2008
High Levels of MicroRNA-126 Bioactivity Specify the LSC Compartment in AML. 112:510. 2008
Natural History of Mesenteric Venous Thrombosis: A Large Multicentre Study. 112:3027-3027. 2008
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial. 112:2767-2767. 2008
Predictors of Osteopenia/Osteoporosis in Children with Acute Lymphoblastic Leukemia.. 112:905-905. 2008
Prospective Evaluation of An Argatroban Dosing Nomogram Using the Ecarin Chromogenic Assay at a Tertiary Institution. 112:3016-3016. 2008
The Efficacy of H. pylori Eradication Therapy in H. pylori-Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review.. 112:3413-3413. 2008
The Impact of Deep Vein Thrombosis on Outcomes in Critically Ill Patients: A Systematic Review and Meta-Analysis. 112:3023-3023. 2008
The Use of IVIG for Solid Organ Transplantation: An Evidence Based Practice Guideline. 112:4666-4666. 2008
Use of Factor VIII/Von Willebrand Factor Complex for Inducing Immune Tolerance in Hemophilia a Patients Who Have Failed with Recombinant Fviii: Recent Canadian Experience. 112:4520-4520. 2008
Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. 112:3029. 2008
Heparin-induced thrombocytopenia: a historical perspective. 112:2607-2616. 2008
“Spare-spleen-uximab” for chronic ITP. 112:925-926. 2008
Targeting LSCs: powering an old tool. 111:5423-5424. 2008
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. 111:4871-4879. 2008
A Negative D-dimer Excludes Recurrent Deep Vein Thrombosis: Results of a Multicentre Management Study.. 110:698-698. 2007
An Individual Platelet Count Set-Point in ITP: A Concept Learned from Patients with Mild Thrombocytopenia and a Good Response to IVIg or Corticosteroids.. 110:3926-3926. 2007
Bone Marrow Cells from Patients with Shwachman-Diamond Syndrome Abnormally Express Ribosomal Protein and Ribosomal Biogenesis-Related Genes.. 110:3303-3303. 2007
Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder.. 110:2148-2148. 2007
Inhibition of the Thrombin-Thrombomodulin by a Covalent Antithrombin-Heparin.. 110:2693-2693. 2007
Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.. 110:189-189. 2007
Risk Factors Predisposing to Thromboembolism in Children with Cancer.. 110:1633-1633. 2007
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. 110:3122-3127. 2007
THAL for THAL?. 110:2788-2789. 2007
α4-Integrin+ endothelium derived from primate embryonic stem cells generates primitive and definitive hematopoietic cells. 109:2406-2415. 2007
ATM deficiency disrupts Tcra locus integrity and the maturation of CD4+CD8+ thymocytes. 109:1887-1896. 2007
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. 109:896-904. 2007
An Algorithm for “Indeterminate” Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT).. 108:1048-1048. 2006
Efficacy of Prothrombin Complex Concentrate (PCC) for Reversal of Warfarin Effect.. 108:964-964. 2006
Evaluation of a VENOus-Return Assist Device (Venowave™) To Treat Severe Post-Thrombotic Syndrome (VENOPTS): A Randomized Controlled Trial.. 108:877-877. 2006
No Evidence for t(14;18)-Positive Cells in Newborns and Young Children until the Age of 10 Followed by a Linear Increase of the Prevalence in Healthy Individuals until the Age of 50 Years.. 108:4281-4281. 2006
Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”).. 108:1047-1047. 2006
Safety and Efficacy of Anti-Fibrinolytics in Orthopedic Surgery: A Meta-Analysis of Randomized Trials.. 108:628-628. 2006
The Management of Anticoagulated Patients Requiring Dental Extraction: A Cross-Sectional Survey of Oral Surgeons and Hematologists.. 108:629-629. 2006
Unexpected Harmful Side Effects Triggered by Immune Modulation.. 108:4008-4008. 2006
Use of Therapeutic Dose Low Molecular Weight Heparin in Patients with Renal Insufficiency: Analysis of Anti-Xa Levels and Creatinine Clearance.. 108:884-884. 2006
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. 108:2937-2941. 2006
Lepirudin: walking the dosing line. 108:1428-1429. 2006
Natural history of cerebral vein thrombosis: a systematic review. 108:1129-1134. 2006
Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. 108:460-464. 2006
Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). 107:3761-3763. 2006
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. 107:2766-2773. 2006
HIT without (more) heparin. 107:2214-2215. 2006
Screening and counseling for thalassemia. 107:1735-1737. 2006
Platelet PECAM-1 inhibits thrombus formation in vivo. 107:535-541. 2006
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. 106:3791-3796. 2005
A Multicenter, Randomized, Controlled Clinical Pilot Trial of the Feasibility of an Intensive RBC Transfusion Policy for Patients with Acute Leukemia Treated with Induction Chemotherapy or Stem Cell Transplant.. 106:4183-4183. 2005
A New Model for Predicting Venesection Therapy Requirements in Hereditary Hemochromatosis Using Non-Invasive Liver Iron Concentration Measurement.. 106:3596-3596. 2005
A Prospective Cohort Study of the Epidemiology of Symptomatic Venous Thromboembolism (VTE) after Isolated Leg Fractures Distal to the Knee without Thromboprophylaxis.. 106:583-583. 2005
A Revisit of the Criteria To Define Remission in Patients with Idiopathic Thrombocytopenia Undergoing Splenectomy.. 106:3020-3020. 2005
Anti-Xa Levels and Renal Function: Analysis of the First 32 Patients in the Tinzaparin in Renal Insufficiency for Venous Thromboembolism Study.. 106:906-906. 2005
Cerebral Sinovenous Thrombosis Post Head Injury - 10 Year Experience in Children.. 106:4132-4132. 2005
High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.. 106:3219. 2005
Incidence of Aspirin ’Resistance’ as Determined Using the PFA-100 in Pediatric Patients with Arterial Ischemic Stroke.. 106:1882-1882. 2005
Intravenous gamma Globulin Does Not Increase RNA Expression of FcgRIIb in Purified Human Monocytes.. 106:3888-3888. 2005
Leukemia-Related Gene Expression of Bone Marrow Cells from Patients with Shwachman-Diamond Syndrome at the Pre-Leukemic Phase.. 106:3433-3433. 2005
Low Molecular Weight Heparin and Bleeding in Patients with Severe Renal Failure: A Meta-Analysis.. 106:907-907. 2005
Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.. 106:2561-2561. 2005
Mechanisms of Static and Shear-Induced Platelet Adhesion: Differences in the Adhesion Supported by MMRN1 Comparisons with Other β3 Integrin Ligands.. 106:2659-2659. 2005
Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.. 106:2568-2568. 2005
PedsQL™ and EuroQol Most Responsive Measures To Change in Health-Related Quality of Life in Children with Hodgkin’s Disease.. 106:1320-1320. 2005
Pregnancy in Thalassemia Patients and Their Partners in a Canadian Population.. 106:3835-3835. 2005
Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. 106:817-817. 2005
Rituximab for the Treatment of Adults with ITP: A Systematic Review.. 106:1241-1241. 2005
The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.. 106:5192-5192. 2005
Thromboembolism in Children with Sarcoma.. 106:4109-4109. 2005
Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT).. 106:1234-1234. 2005
Use of Low Dose Oral Vitamin K in the Treatment of Patients with INR Values of More Than 10.0.. 106:547-547. 2005
Unfractionated LMWH and the risk of HIT: are medical patients different?. 106:2931-2932. 2005
HIT as a preventable disease?. 106:2600-2600. 2005
Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. 106:2921-2922. 2005
Human embryonic stem cells maintained in the absence of mouse embryonic fibroblasts or conditioned media are capable of hematopoietic development. 105:4598-4603. 2005
Patients with thalassemia in the United States. 105:4896-4897. 2005
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. 105:4043-4050. 2005
Challenging the role of Notch in HSC biology. 105:2248-2248. 2005
Smad7 alters cell fate decisions of human hematopoietic repopulating cells. 105:1905-1915. 2005
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. 105:1734-1741. 2005
New anticoagulants. 105:453-463. 2005
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. 105:855-861. 2005
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. 105:139-144. 2005
Patients with severe sepsis vary markedly in their ability to generate activated protein C. 104:3958-3964. 2004
A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).. 104:3464-3464. 2004
A Prospective Cohort Study of the Epidemiology of Symptomatic Venous Thromboembolism (VTE) after Isolated Leg Fractures Distal to the Knee without Thromboprophylaxis.. 104:492-492. 2004
Anti-Xa Levels in Critically Ill Patients Receiving Dalteparin for Thromboprophylaxis.. 104:4075-4075. 2004
Comparison of Compression Ultrasound vs Ascending Contrast Venography for Proximal DVT in Medical-Surgical ICU Patients.. 104:2603-2603. 2004
Inhibition of Factor Xa in Prothrombinase Is Enhanced by Covalent Linkage of Antithrombin to Heparin.. 104:1051-1051. 2004
Laboratory Testing for Hit Antibodies: How Much Class Do We Need?.. 104:3022-3022. 2004
Safety and Efficacy of Venous Thromboembolism Prophylaxis with Low Molecular Weight Heparin in Hospitalised Patients with Acute Medical Illness and Renal Failure.. 104:4078-4078. 2004
Survival of HIV Infected Individuals with Hemophilia after 20 Years: From the Canadian Hemophilia Registry.. 104:3085-3085. 2004
The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.. 104:4939-4939. 2004
The Risk of Hemorrhage and the Frequency of Vitamin K Use in Asymptomatic Patients with Warfarin-Associated Coagulopathy.. 104:527-527. 2004
Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.. 104:4917-4917. 2004
Bleeding risks associated with inheritance of the Quebec platelet disorder. 104:159-165. 2004
Subspeciality training in hematology and oncology, 2003: results of a survey of training program directors conducted by the American Society of Hematology. 103:4383-4388. 2004
Differential gene expression of human stem progenitor cells derived from early stages of in utero human hematopoiesis. 103:2530-2540. 2004
VEGF-A165 augments erythropoietic development from human embryonic stem cells. 103:2504-2512. 2004
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. 103:804-810. 2004
Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. 103:93-99. 2004
A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. 102:4306-4311. 2003
Neutrophils and the protein C pathway. 102:1152-1153. 2003
Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. 102:906-915. 2003
Deferiprone and hepatic fibrosis. 101:5089-5091. 2003
Central venous line–related thrombosis in children: association with central venous line location and insertion technique. 101:4273-4278. 2003
Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. 101:3049-3051. 2003
Heparin-induced thrombocytopenia in medical patients. 101:2903-2903. 2003
Hemoglobin H disease: not necessarily a benign disorder. 101:791-800. 2003
Emergence of muscle and neural hematopoiesis in humans. 100:3193-3202. 2002
The mechanism of action of high-dose IgG in idiopathic thrombocytopenic purpura. 100:1933-1934. 2002
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. 100:1525-1531. 2002
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. 100:1566-1569. 2002
Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. 100:869-878. 2002
Engraftment potential of human fetal hematopoietic cells in NOD/SCID mice is not restricted to mitotically quiescent cells. 100:120-127. 2002
Expression of the β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. 100:96-106. 2002
How we diagnose and treat deep vein thrombosis. 99:3102-3110. 2002
Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa–based methods overestimate antithrombin activity in some patients?. 99:2271-2272. 2002
Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. 99:1817-1824. 2002
Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. 99:1817-1824. 2002
Reduced tissue macrophage population in the lung by anticancer agent cyclophosphamide: restoration by local granulocyte macrophage–colony-stimulating factor gene transfer. 99:1246-1252. 2002
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. 98:1842-1846. 2001
Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. 98:257-265. 2001
Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke. 98:36-40. 2001
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. 97:3727-3732. 2001
Treatment of adults with ITP: less may be more. 97:2533-2533. 2001
Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. 97:1960-1967. 2001
Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. 97:1960-1967. 2001
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. 97:1211-1218. 2001
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. 97:844-849. 2001
A prospective cross-sectional study to characterize selected autoimmune (AI) markers and report the incidence of antithrombopoietin antibodies (aTPO) in patients with immune thrombocytopenic purpura (ITP). 96. 2000
All trans retinoic acid (atra) fails to upregulate retevoic acid receptor beta (rar β) in a non m3 acute myelogenous leukemia cell line. 96. 2000
Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD). 96. 2000
Assessing pore formation by BCL-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment. 96. 2000
Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. 96. 2000
Cardiac myocytes, an inducible source of tissue type plasminogen activator production: potential implications in fibrinolysis and wound healing following myocardial infarction. 96. 2000
Comparison of post transfusion platelet response following random donor and apheresis platelets. 96. 2000
Cytokine responsiveness of circulating human embryonic hematopoietic stem cells is unique compared to other stages of human ontogeny. 96. 2000
Effect of hormone replacement therapy on the endogenous thrombin potential. 96. 2000
Effectiveness of reconstituted and then frozen tpa for dysfunctional percutaneous dialysis catheters. 96. 2000
Endogenous thrombin potential and the risk of venous thromboembolism. 96. 2000
Evaluation of platelet morphology and the subcellular distribution of PAIgG in patients with ITP and non-immune thrombocytopenia. 96. 2000
Expression of cd109 with alternate forms of membrane anchoring unique to platelets and megakaryocytic cell lines. 96. 2000
Hemocbromatosbdueto aceruloplasmbnemia: Treatment of an adult caucasian. 96. 2000
Human cord blood lin-cd45- cells are capable of both hematopoietic and chondrocytic function. 96. 2000
Human homologs of delta-1 and delta-4 function as mitogenic regulators of primitive human hematopoietic cells. 96. 2000
Identification of the mechanism responsible for the decreased fibrin specificity of reteplase relative to tissue-type plasminogen activator. 96. 2000
Identification of vesicular stomatitis virus as a leukemolytic agent. 96. 2000
Incorporation of fragment x into clots increases their susceptibility to lysis. 96. 2000
Induction of hematopoietic cell fate from neuronal and muscle cells in the human. 96. 2000
Isolation of cd34-ac133+lin- cells from the human stem cell compartment reveals superior retroviral transduction to that of cd34+cd38-lin-. 96. 2000
Laboratory screening for hemoglobinopathies in the province of ontario: Proficiency and patterns of practice. 96. 2000
Patients with multiple myeloma transplanted with increased numbers of pbpc demonstrate early recovery of total lymphocytes. 96. 2000
Phase i-n trial of vacop-b + filgrastim (g-csf) support for hiv-related non-hodgkins lymphoma (nhl). 96. 2000
Phospholipid micelles, but not vesicles, neutralize heparin: an explanation for the minimal effect of heparin on the prothrombin time. 96. 2000
Population screening, molecular confirmation, and prevalence of hemoglobin H disease among newborns in California. 96. 2000
Possible pathways of IGG trafficking in platelets. 96. 2000
Quantitative frequency analysis of human stem cells in ex vivo cultures reveals the existence of a PRE-SCID repopulating cell (PRE-SRC). 96. 2000
Sickle cell disease in a four year old child with apparent HBS trait. 96. 2000
Site-directed mutagenesis at p6 in heparin cofactorii creates a thrombin-inhibitory serpin that is resistant to neutrophil elastaseinac1tvation. 96. 2000
The impact of idiopathic thrombocytopenic purpura in pregnancy. 96. 2000
Treatment of chronic refractory idiopathic thrombocytopenic purpura with cyclophosphamide and cyclosporine. 96. 2000
Use of vitamin k to reverse warfarin-induced excessive anticoagulation: a survey of current practice habits. 96. 2000
Identification of novel circulating human embryonic blood stem cells. 96:1740-1747. 2000
Impact of the patient population on the risk for heparin-induced thrombocytopenia. 96:1703-1708. 2000
Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. 96:188-194. 2000
Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. 96:188-194. 2000
Isolation and characterization of human CD34−Lin− and CD34+Lin− hematopoietic stem cells using cell surface markers AC133 and CD7. 95:2813-2820. 2000
Abundance of cyclin B1 regulates γ-radiation–induced apoptosis. 95:2645-2650. 2000
Abundance of cyclin B1 regulates γ-radiation–induced apoptosis. 95:2645-2650. 2000
Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. 95:2337-2345. 2000
Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-hodgkin's lymphoma. 96. 2000
Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients. 94:3007-3014. 1999
Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients. 94:3007-3014. 1999
Multimerin Processing by Cells With and Without Pathways for Regulated Protein Secretion. 94:1337-1347. 1999
Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. 94:959-967. 1999
Embryonic Hemoglobins Are Expressed in Definitive Cells. 94:359-361. 1999
Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. 93:3442-3450. 1999
A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. 93:1231-1236. 1999
Etretinate Therapy for Refractory Sclerodermatous Chronic Graft-Versus-Host Disease. 93:66-70. 1999
Etretinate Therapy for Refractory Sclerodermatous Chronic Graft-Versus-Host Disease. 93:66-70. 1999
Treatment of Non-Obese Diabetic (NOD)/Severe-Combined Immunodeficient Mice (SCID) With flt3 Ligand and Interleukin-7 Impairs the B-Lineage Commitment of Repopulating Cells After Transplantation of Human Hematopoietic Cells. 92:2024-2031. 1998
Treatment of Non-Obese Diabetic (NOD)/Severe-Combined Immunodeficient Mice (SCID) With flt3 Ligand and Interleukin-7 Impairs the B-Lineage Commitment of Repopulating Cells After Transplantation of Human Hematopoietic Cells. 92:2024-2031. 1998
An electronic database of human hemoglobin variants on the World Wide Web.. 91:2643-2644. 1998
Hydrops Fetalis Caused by α-Thalassemia: An Emerging Health Care Problem. 91:2213-2222. 1998
Studies of Multimerin in Human Endothelial Cells. 91:1304-1317. 1998
In Vivo Adenoviral-Mediated Gene Transfer of Interleukin-2 in Cutaneous Plasmacytoma. 91:1095-1097. 1998
Factor VII Deficiency Caused by a Structural Variant N57D of the First Epidermal Growth Factor Domain. 91:142-148. 1998
A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. 89:3236-3242. 1997
Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin. 89:3243-3252. 1997
Acute idiopathic thrombocytopenic purpura - Management in childhood - Response. 89:1466-1466. 1997
Acute idiopathic thrombocytopenic purpura--management in childhood.. 89:1465. 1997
Studies of a Second Family With the Quebec Platelet Disorder: Evidence That the Degradation of the α-Granule Membrane and Its Soluble Contents Are Not Secondary to a Defect in Targeting Proteins to α-Granules. 89:1243-1253. 1997
Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. 88:1314-1320. 1996
Humoral immune response limits gene therapy in canine MPS I [letter]. 88:377-379. 1996
Humoral immune response limits gene therapy in canine MPS I [letter]. 88:377-379. 1996
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]. 88:3-40. 1996
An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. 87:4967-4978. 1996
Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. 87:5095-5103. 1996
Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. 87:5061-5073. 1996
Antiphospholipid antibodies and venous thromboembolism. 86:3685-3691. 1995
Intracellular events determine the fate of antithrombin Utah. 86:3461-3467. 1995
Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. 86:2807-2814. 1995
Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. 86:2807-2814. 1995
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. 86:1368-1373. 1995
Human embryonic zeta-globin gene expression in mouse-human hybrid erythroid cell lines. 86:1212-1217. 1995
Telomerase activity in normal leukocytes and in hematologic malignancies. 85:2315-2320. 1995
The leukodepletion of cellular blood products in the prevention of HLA- alloimmunization and refractoriness to allogeneic platelet transfusions [editorial]. 85:603-606. 1995
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. 84:3691-3699. 1994
Biologic effects of leukocytes present in transfused cellular blood products. 84:1703-1721. 1994
Identification of a novel termination codon mutation (TAA-->TAT, Term-- >Tyr) in the alpha 2 globin gene of a Laotian girl with hemoglobin H disease [letter]. 83:3418-3420. 1994
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. 83:3232-3239. 1994
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. 83:3232-3239. 1994
Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. 83:2230-2237. 1994
Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments]. 81:2958-2963. 1993
Expression of embryonic zeta-globin and epsilon-globin chains in a 10- year-old girl with congenital anemia. 81:1636-1640. 1993
Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. 80:2246-2251. 1992
Molecular basis of inherited human antithrombin deficiency. 80:2159-2171. 1992
Molecular basis of inherited human antithrombin deficiency. 80:2159-2171. 1992
Maturation of the hemostatic system during childhood. 80:1998-2005. 1992
Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. 80:1758-1764. 1992
Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells. 80:1486-1495. 1992
The T----C substitution at nucleotide + 1570 of the beta-globin gene is a polymorphism [letter; comment]. 80:1365-1365. 1992
Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study [see comments]. 80:975-980. 1992
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. 80:960-965. 1992
Evidence that interleukin-6 does not play a role in the stimulation of platelet production after induction of acute thrombocytopenia. 80:346-351. 1992
Human embryonic zeta-globin chain expression in deletional alpha- thalassemias. 80:517-522. 1992
Inadequate monitoring of warfarin dosage [letter] [see comments]. 80:562-563. 1992
Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. 79:2952-2959. 1992
Molecular cloning and expression of rabbit antithrombin III. 79:2330-2339. 1992
Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). 79:2480-2484. 1992
Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). 79:2480-2484. 1992
Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. 79:1428-1434. 1992
Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. 79:1428-1434. 1992
2 NOVEL BETA-THALASSEMIA MUTATIONS IN THE 5' AND 3' NONCODING REGIONS OF THE BETA-GLOBIN GENE. 79:1342-1346. 1992
An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion. 79:1371-1375. 1992
Two novel beta-thalassemia mutations in the 5' and 3' noncoding regions of the beta-globin gene [see comments]. 79:1342-1346. 1992
Basophil and mast cell lineages in vitro and in vivo [published erratum appears in Blood 1992 Aug 1;80(3):855]. 79:846-860. 1992
A human monoclonal autoantibody to platelet glycoprotein IIb derived from normal human lymphocytes. 79:447-451. 1992
Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. 79:356-364. 1992
Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. 79:356-364. 1992
Low molecular weight heparin. 79:1-17. 1992
Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. 78:2299-2304. 1991
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia [see comments]. 78:2194-2197. 1991
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia [see comments]. 78:2194-2197. 1991
Investigation of the mechanisms of monoclonal antibody-induced platelet activation. 78:1019-1026. 1991
Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor. 78:599-601. 1991
Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. 77:2569-2576. 1991
Multimerin: a series of large disulfide-linked multimeric proteins within platelets. 77:2556-2560. 1991
Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. 77:2185-2189. 1991
A molecular genetic study of factor XI deficiency. 77:1942-1948. 1991
Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. 77:1462-1468. 1991
High hemoglobin A2 beta 0-thalassemia due to a 532-basepair deletion of the 5' beta-globin gene region.. 77:1100-1103. 1991
Synergistic effects of nerve growth factor and granulocyte-macrophage colony-stimulating factor on human basophilic cell differentiation. 77:971-979. 1991
Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin. 76:1521-1529. 1990
Gova/b alloantigen system on human platelets. 75:2172-2176. 1990
Gova/b alloantigen system on human platelets. 75:2172-2176. 1990
Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. 75:1081-1086. 1990
Recurrent acute splenic sequestration crisis due to interacting genetic defects: hemoglobin SC disease and hereditary spherocytosis. 75:266-270. 1990
Human embryonic zeta-globin chains in fetal and newborn blood. 74:1409-1414. 1989
Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide. 74:1036-1044. 1989
The T-cell receptor delta chain locus is disrupted in the T-ALL associated t(11;14)(p13;q11) translocation. 73:1672-1676. 1989
A novel monoclonal antibody based diagnostic test for alpha-thalassemia- 1 carriers due to the (-SEA/) deletion. 72:1589-1594. 1988
Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. 72:1518-1523. 1988
Development of the human coagulation system in the healthy premature infant. 72:1651-1657. 1988
Heparin-induced thrombocytopenia: laboratory studies. 72:925-930. 1988
Heparin-induced thrombocytopenia: laboratory studies. 72:925-930. 1988
Behavior of plasminogen at the luminal surface of the normal and deendothelialized rabbit aorta in vivo and in vitro. 71:1260-1267. 1988
An immunoassay to detect human embryonic epsilon globin chains by a murine monoclonal antibody. 71:883-887. 1988
Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. 71:932-939. 1988
Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. 71:932-939. 1988
Rearrangement and expression of T cell antigen receptor genes in B cell chronic lymphocytic leukemia. 71:178-185. 1988
Sodium butyrate and a T lymphocyte cell line-derived differentiation factor induce basophilic differentiation of the human promyelocytic leukemia cell line HL-60. 71:209-215. 1988
Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. 70:1683-1687. 1987
111In-oxine platelet survivals in thrombocytopenic infants. 70:652-656. 1987
IN-111 OXINE PLATELET SURVIVALS IN THROMBOCYTOPENIC INFANTS. 70:652-656. 1987
Development of the human coagulation system in the full-term infant. 70:165-172. 1987
Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia. 69:1294-1299. 1987
Studies investigating platelet aggregation and release initiated by sera from patients with thrombotic thrombocytopenic purpura. 69:924-928. 1987
Classifying acute leukemia by immunophenotyping: a combined FAB- immunologic classification of AML. 68:1355-1362. 1986
Spurious detection of terminal deoxynucleotidyl transferase in phytohemagglutinin-stimulated lymphocytes. 68:310-312. 1986
Development of a radioimmunoassay for the fibrinogen-derived peptide B beta 1-42. 67:1014-1022. 1986
On the interaction of rabbit antithrombin III with the luminal surface of the normal and deendothelialized rabbit thoracic aorta in vitro. 67:878-886. 1986
Hemoglobin switching during murine embryonic development: evidence for two populations of embryonic erythropoietic progenitor cells. 67:716-721. 1986
A diagnostic test for heparin-induced thrombocytopenia. 67:27-30. 1986
Detection of terminal deoxynucleotidyl transferase [letter]. 66:1006-1007. 1985
The concentration of IgG in the serum is a major determinant of Fc- dependent reticuloendothelial function. 66:490-495. 1985
The concentration of IgG in the serum is a major determinant of Fc- dependent reticuloendothelial function. 66:490-495. 1985
Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. 66:312-318. 1985
Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. 66:399-401. 1985
Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia. 65:142-148. 1985
The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. 65:198-201. 1985
Regulation of normal human granulopoiesis in vitro by autologous T lymphocyte subsets [letter]. 64:1139-1140. 1984
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. 64:742-747. 1984
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.. 64:742-747. 1984
The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function. 63:1434-1438. 1984
The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function. 63:1434-1438. 1984
T cell surface antigens in blast crisis of CML [letter]. 63:970-971. 1984
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. 63:525-531. 1984
Adult hemoglobins are synthesized in murine fetal hepatic erythropoietic cells. 62:1280-1288. 1983
The amount of platelet-bound albumin parallels the amount of IgG on washed platelets from patients with immune thrombocytopenia. 62:924-927. 1983
The amount of platelet-bound albumin parallels the amount of IgG on washed platelets from patients with immune thrombocytopenia. 62:924-927. 1983
Basophil/mast cell precursors in human peripheral blood. 61:775-780. 1983
Changes in phosphatidylinositol-4,5-bisphosphate 10 seconds after stimulation of washed rabbit platelets with ADP. 60:1247-1250. 1982
The inhibitory effects of exogenous arachidonic acid on rabbit platelet aggregation and the release reaction. 60:1179-1187. 1982
A prospective study of the usefulness of the measurement of platelet- associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. 60:1050-1053. 1982
Abnormal erythroid progenitor cells in human preleukemia. 60:362-367. 1982
Effect of modulators of erythropoiesis on the hemoglobinization of human erythroid cell cultures. 60:346-351. 1982
Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. 60:113-120. 1982
The quantitation of platelet-associated IgG on cohorts of platelets separated from healthy individuals by buoyant density centrifugation. 60:136-139. 1982
The quantitation of platelet-associated IgG on cohorts of platelets separated from healthy individuals by buoyant density centrifugation. 60:136-139. 1982
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. 59:1239-1245. 1982
The amount of blood group A substance on platelets is proportional to the amount in the plasma. 59:980-985. 1982
Sex related differences in platelet function: the effect of aspirin. 59:625-627. 1982
The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. 59:346-350. 1982
Phenotypic characterization of human bone marrow granulocyte-macrophage forming progenitor cells. 58:1047-1049. 1981
Plasma and urine beta-thromboglobulin concentration in patients with deep vein thrombosis. 58:693-698. 1981
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro. 58:524-529. 1981
Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. 58:326-329. 1981
Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. 58:326-329. 1981
Iron incorporation into ferritin and hemoglobin during differentiation of murine erythroleukemia cells. 58:255-262. 1981
The reversible binding of vinblastine to platelets: implications for therapy. 57:431-438. 1981
Blood tests for the diagnosis of venous and arterial thrombosis. 57:1-8. 1981
Immunodepletion of human plasma factor VIII. 56:604-607. 1980
Sex-related differences in platelet aggregation: influence of the hematocrit. 56:38-41. 1980
Sex-related differences in platelet aggregation: influence of the hematocrit. 56:38-41. 1980
Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. 56:88-92. 1980
Comparison of two direct assays for platelet-associated IgG (PAIgG) in assessement of immune and nonimmune thrombocytopenia. 55:424-429. 1980
Comparison of two direct assays for platelet-associated IgG (PAIgG) in assessement of immune and nonimmune thrombocytopenia. 55:424-429. 1980
Decreased platelet thrombogenecity in association with increased platelet turnover and vascular damage. 54:1369-1375. 1979
An improved method for studying the elastic properties of erythrocyte membranes. 54:1069-1079. 1979
Plasma beta-thromboglobulin: differentiation between intravascular and extravascular platelet destruction. 54:1192-1196. 1979
Fetal erythropoiesis and hemoglobin ontogeny in tail-short (Ts/+) mutant mice. 54:673-683. 1979
The direct assay for platelet-associated IgG (PAIgG): lack of association between antibody level and platelet size. 53:73-80. 1979
The direct assay for platelet-associated IgG (PAIgG): lack of association between antibody level and platelet size. 53:73-80. 1979
Sex differences in the antithrombotic effects of aspirin. 52:1073-1076. 1978
Sex differences in the antithrombotic effects of aspirin. 52:1073-1076. 1978
Effect of viruses on platelet aggregation and platelet survival in rabbits. 52:47-55. 1978
Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. 51:1189-1195. 1978
Fetal erythropoiesis in steel mutant mice. III. Defect in differentiation from BFU-E to CFU-E during early development. 51:539-547. 1978
Hemoglobin synthesis in siderocytes of flexed-tailed mutant (f/f) fetal mice. 50:165-177. 1977
Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. 49:171-184. 1977
The effect of experimental hematoma on serum levels of fibrinogen- related antigen. 47:855-859. 1976
Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism. 45:563-568. 1975
ERYTHROPOIESIS IN STEEL MUTANT MICE - EFFECTS OF ERYTHROPOIETIN INVITRO. 45:427-433. 1975
Erythrocyte Coproporphyrin and Protoporphyrin in Ethanol-induced Sideroblastic Erythropoiesis. 43:291-295. 1974
Von Willebrand's Syndrome Presenting as an Acquired Bleeding Disorder in Association With a Monoclonal Gammopathy. 42:429-436. 1973
Relation Between Bleeding Time and Platelet Connective Tissue Reaction After Aspirin. 41:369-377. 1973
Fetal Effects of Coumadin Administered During Pregnancy. 36:623-627. 1970
Effect of Streptokinase on Hemostasis. 32:726-737. 1968
Immunocytochemical localization of fibrinogen on washed human platelets. Lack of requirement for fibrinogen during adenosine diphosphate-induced responses and enhanced fibrinogen binding in a medium with low calcium levels 1988
Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with low concentration of ionized calcium 1987
Effects on the buoyant density of rabbit platelets of ADP and agents that increase the concentration of cyclic AMP \textbar Request PDF 1985
Platelet sialic acid and platelet survival after aggregation by ADP 1980
The Effect of Pretreatment of Human or Rabbit Platelets With Chymotrypsin on Their Responses to Human Fibrinogen and 1979
Reactions of 14C-ADP and 14C-ATP with washed platelets from rabbits 1971
Interactions of polylysine with platelets 1971

Blood Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)